[go: up one dir, main page]

US20190022425A1 - Device And Method for Non-Invasive Neuromodulation - Google Patents

Device And Method for Non-Invasive Neuromodulation Download PDF

Info

Publication number
US20190022425A1
US20190022425A1 US16/037,974 US201816037974A US2019022425A1 US 20190022425 A1 US20190022425 A1 US 20190022425A1 US 201816037974 A US201816037974 A US 201816037974A US 2019022425 A1 US2019022425 A1 US 2019022425A1
Authority
US
United States
Prior art keywords
neural structure
neural
sound waves
target
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/037,974
Inventor
Karl Deisseroth
M. Bret Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to US16/037,974 priority Critical patent/US20190022425A1/en
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY reassignment THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEISSEROTH, KARL, SCHNEIDER, M. BRET
Publication of US20190022425A1 publication Critical patent/US20190022425A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0004Applications of ultrasound therapy
    • A61N2007/0021Neural system treatment
    • A61N2007/0026Stimulation of nerve tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0078Ultrasound therapy with multiple treatment transducers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N2007/0086Beam steering
    • A61N2007/0095Beam steering by modifying an excitation signal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00Ultrasound therapy
    • A61N7/02Localised ultrasound hyperthermia
    • A61N2007/027Localised ultrasound hyperthermia with multiple foci created simultaneously

Definitions

  • the present invention relates generally to systems and approaches for stimulation of neural circuits and more particularly to facilitating long-term potentiation or long-term depression between neural circuits.
  • LTP Long-term potentiation
  • Hebb's rule essentially states that if an axon of cell A is near enough to excite a cell B and repeatedly or persistently takes part in firing cell B, an increase in the strength of the chemical synapse between the cells takes place such that A′s efficiency, as one of the cells firing B, is increased.
  • LTP has been shown to last from minutes to several months. Conditions for establishing LTP are favorable when a pre-synaptic neuron and a post-synaptic neuron are both depolarized in a synchronous manner. An opposite effect, long-term depression (LTD), has also been established.
  • LTD is the weakening of a neuronal synapse that lasts from hours to months.
  • LTD results from strong synaptic stimulation.
  • LTD results from persistent weak synaptic stimulation, or when a pre-synaptic neuron and a postsynaptic neuron discharge in an asynchronous manner.
  • Hebb's Rules have been proposed for the prediction of self-organization of neuronal systems, and these rules appear to govern the process by which the brain is effectively sculpted over time in order to master the demands of the environment.
  • Neurons and other electrically excitable cells have spontaneous firing rates: they discharge action potentials at a baseline rate, in the absence of external stimulation or suppression. This spontaneous firing rate is affected by temperature. Generally, the warmer an electrically excitable cell, the faster the spontaneous firing rate, and the colder the cell, the slower the firing rate. When cells become extremely warm, such as in a very high fever, they have a high propensity to fire. At extremes, such an increase in firing rates may manifest as a risk of a febrile seizure.
  • Neuromodulation is the control of nerve activity, and is usually implemented for the purpose of treating disease. In the strictest sense, neuromodulation may be accomplished with a surgical intervention like cutting an aberrant nerve tract. However, the semi-permanent nature of a surgical procedure leaves little room for later adjustment and optimization. Likewise, it could be asserted that neuromodulation can be accomplished with chemical agents or medications. Chemical agents or medications may be undesirable because, for example, many medications are difficult to deliver to specific anatomy, and because the titration (increasing or decreasing the dose of a medication) is a slow and imprecise way to achieve a desired effect on a specific target. Consequently, the term neuromodulation usually implies the use of energy-delivering devices.
  • TENS transcutaneous electrical nerve stimulation
  • DBS deep brain stimulation
  • a multi-contact electrode may be neurosurgically implanted in the subthalamic nucleus of a patient.
  • the electrodes Once connected to a pulse generation unit similar to a cardiac pacemaker device, the electrodes may be electrically pulsed at various rates, effectively driving the activity of the neurons immediately adjacent to the electrode contacts, using currents of about 3 amps and voltages between 1 and 10.
  • various configurations of electrode pairs or monopolar configurations may be empirically tested on the patient for effect and tolerability.
  • the circuit configuration or pulse parameters may be changed by the physician in charge, usually without the need to physically disturb the implanted electrode.
  • DBS One disadvantage of DBS is that, by definition, it requires a highly invasive and risky neurosurgical implantation procedure. If the site of implantation is later deemed suboptimal, or if the device physically fails, more surgery is required.
  • Magnetic stimulation involves the discharge of large capacitors into an electrically conductive coil placed external to a patient's brain or body. As electrical current runs through the coil, a magnetic field is induced, which in turn, induces an electric field in nerve membranes and surrounding fluid. This forces nerves to depolarize with each discharge of the capacitors in the machine. Magnetic stimulation, when delivered at rates of 5-20 Hz, tend to be stimulating to nerves that it affects, for some time after the magnetic pulse delivery has stopped. Pulse rates of less than 1 Hz tend to suppress the activity of affected nerves after stimulation has ended. Very fast pulse trains (e.g., 50 Hz), punctuated by absence of pulses 6-9 times per second (“theta rhythm”) also tend to suppress the activity of affected neurons.
  • Very fast pulse trains e.g., 50 Hz
  • theta rhythm also tend to suppress the activity of affected neurons.
  • Magnetic neuromodulation in the form of repetitive transcranial magnetic stimulation, is useful for the treatment of depression, and likely several other neurological and psychiatric conditions.
  • the derived effects may last from minutes to months after the end of magnetic treatment.
  • One limitation of magnetic neuromodulation is the difficulty in achieving tight focus of the effect, since magnetic fields capable of penetrating to useful depth tend to be large in footprint, as dictated by the Biot-Savart Law.
  • Opto-genetic neuromodulation is a newly discovered approach which has the advantages of being neuron-type specific. Using this approach, light-sensitive ion channels or pumps are genetically transferred to the targeted neurons of the brain to be stimulated. A flashing light from an implanted device provides a signal to these channels or pumps to activate. This leads to either neuronal depolarization, or neuronal hyperpolarization, depending upon the nature of the light-sensitive channel or pump. Opto-genetic approaches lend themselves to both neuronal up-regulation and down-regulation. Disadvantages include the requirement of implanted hardware, and the need for the genetic modification of targeted neurons.
  • Ultrasound is mechanical vibration at frequencies above the range of human hearing, or above 16 kHz. Most medical uses for ultrasound use frequencies in the range of 1 to 20 MHz. Low to medium intensity ultrasound products are widely used by physicians, nurses, physical therapists, masseurs and athletic trainers. The most common applications are probably warmthing stiff, swollen or painful joints or muscles in a manner similar to a hot compress, but with better penetration. Many ultrasound products have been commercially available for years, including consumer-grade massage machines. By design, the power on these devices is designed to be too low to warm or otherwise affect structures more than two centimeters or so below the surface. Also, these devices are not capable of tight focus at depth, nor are there means for accurately aiming such devices toward precise structural coordinates within the body. As ultrasound of sufficient strength can cause pain in peripheral nerves with each pulse, it is likely that mechanical perturbations caused by ultrasound can cause nerves to discharge.
  • the present invention is directed to methods, devices and systems that are used to modify neural transmission patterns between neural structures and/or regions. Consistent herewith, one exemplary method involves directing sound waves toward a first targeted neural structure, controlling characteristics of the sound waves at the first target neural structure with respect to characteristics of sound waves at the second target neural structure, and in response, modifying neural transmission patterns.
  • a transducer produces the sound for stimulating the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the sound waves as described above to modify the neural transmission patterns between the first and second neural structures.
  • the present invention is directed to methods, devices and systems that are used to modify neural transmission patterns between neural structures and/or regions. Consistent herewith, one exemplary method involves directing stimuli toward a first targeted neural structure, controlling characteristics of the stimulus at the first target neural structure with respect to characteristics of stimulus at the second target neural structure, and in response, modifying neural transmission patterns.
  • a transducer produces the stimulus for the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the stimulus as described above to modify the neural transmission patterns between the first and second neural structures.
  • FIG. 1 shows a system for altering neural patterns between two groups of cells, according to an example embodiment of the present invention
  • FIG. 2A shows the use of two focused-beam ultrasound transducers physiologically suppressing the connection between two regions, according to an example embodiment of the present invention
  • FIG. 2B shows the use of an electronically focused ultrasound transducer array to physiologically augment the connection between two regions, according to an example embodiment of the present invention
  • FIG. 3A shows a specific application of the present invention in which LTP is facilitated within the “trisynaptic circuit” of the human hippocampus, according to an example embodiment of the present invention
  • FIG. 3B shows the use of the present invention, to produce LTP between the entorhinal cortex and the CA3 fields of a human hippocampus, as can be used to augment the encoding of memory, according to an example embodiment of the present invention
  • FIG. 4A shows the use of two focused-beam ultrasound transducers, each focused upon a different, but connected neural target, according to an example embodiment of the present invention.
  • FIG. 4B shows an array of multiple small ultrasound transducers which may be electronically directed at one or more target regions within a patient's brain via a coordinated phase and power adjustment, also according to the present invention.
  • the present invention is believed to be useful for enabling practical application of a variety of LTP and LTD systems, and the invention has been found to be particularly suited for use in systems and methods dealing with generating LTP or LTD effects in neural circuits through the use of sounds waves (which may include high-intensity focused ultrasound), radio frequency (RF) transmissions, electrical current, magnetic fields or ionizing radiation.
  • sounds waves which may include high-intensity focused ultrasound
  • RF radio frequency
  • Various embodiments of the present invention are directed toward the use of ultrasound to produce LTP or LTD within a living subject. Sound waves are used to stimulate a first portion of neurons. For LTP, the sound waves are used to concurrently stimulate a second portion of neurons in a synchronous manner. For LTD, the sound waves are used to stimulate a second portion of neurons in an asynchronous manner. Sound waves provide stimulation both in terms of thermal properties and mechanical jarring. While specific embodiments and applications thereof involve sound waves being in the ultrasound frequency range, they need not be so limited. For example, aspects of the present invention can employ frequencies that are outside of the ultrasound frequency range.
  • the present invention is directed to a method for modifying neural transmission patterns between neural structures.
  • the method involves producing and directing sound waves or RF transmissions toward a first targeted neural structure, controlling characteristics of the sound waves or RF transmissions at the first target neural structure with respect to characteristics of sound waves or RF transmissions at the second target neural structure, and thereby modifying neural transmission patterns.
  • a transducer produces the sound for stimulating the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the sound waves as described above to modify the neural transmission patterns between the first and second neural structures.
  • a RF transmitter is used to produce RF transmissions and to focus the transmissions toward a first target neural structure.
  • the present invention uses High-intensity Focused Ultrasound (HIFU) as a powerful ultrasound emitter.
  • HIFU High-intensity Focused Ultrasound
  • ultrasound waves are aimed and focused at a targeted depth geometrically, for example, by using a lens at the emitting end, or by using a curved transducer portion (e.g., a partial sphere).
  • Ultrasound may also be aimed and focused electronically, by coordinating the phase and intensity of individual transducer elements within an array, thereby steering the location of greatest intensity, and even correcting for transmission distortions created, for example by inhomogeneities in the skull.
  • the mechanical excitation of the tissue generates heat.
  • the focal point of a HIFU system may be heated substantially in response to the ultrasound.
  • the threshold for cell death is generally bringing the targeted tissue to 56 degrees Celsius for one second, or 52 degrees Celsius for a longer period of time. Also, tissues held above 43 degrees Celsius for more than an hour or so may have their physiological processes (including cell division) interrupted. Accordingly, to change the firing patterns of targeted neurons, the temperature can be raised to a more moderate temperature above the normal 37 degrees Celsius. In another example, the targeted neurons may be raised to 40-42 degrees Celsius for repeated, brief periods of time, resulting in an increased spontaneous firing rate, and enabling one step of the LTP/LTD induction process.
  • HIFU is used to stimulate two different areas of the brain.
  • the stimulation of each area is coordinated in order to facilitate the development of either LTP or LTD between the two different areas of the brain.
  • each of the areas can be stimulated in a synchronous fashion to produce LTP. If the stimulation results in an increased rate of depolarization of the neurons, the probability that both areas of the brain will fire at the same time is likewise increased.
  • LTP may be developed where the stimulation results in one of the areas generating action potentials more readily in response to stimulus from the other area (e.g., by having a lower depolarization threshold).
  • the areas may be stimulated in an asynchronous fashion to produce an increased probability of the different areas firing independently from one another.
  • FIG. 1 shows a system for altering neural patterns between two groups of cells, according to an example embodiment of the present invention.
  • Ultrasound (or RF) source 104 focuses the ultrasound (or RF) 106 , 108 at locations 110 and 114 .
  • the ultrasound can be focused at only one of the locations, or at one location at a time (e.g., for developing LTD).
  • Control 102 controls the ultrasound produced by ultrasound source 104 .
  • control 102 is responsive to input from monitor device 116 .
  • the stimulation from sound (or RF) 106 , 108 can be used to effect (e.g., facilitate or frustrate through LTP or LTD) a pathway 112 between locations 110 and 114 .
  • Ultrasound source 104 can be implemented using a number of different techniques and mechanisms. According to one embodiment, ultrasound source 104 is implemented using one single transducer for each of location 110 and 114 . Such a transducer acts as a lens to focus the ultrasound waves at a point in space.
  • the control 104 can modify various aspects of the transducer including, but not limited to, direction of focus, distance from the target location, strength of the ultrasound waves or the frequency of the ultrasound waves. Such aspects allow for precise aiming of the focal point of the ultrasound waves. This can be particularly useful for reducing unintended stimulation of cells while increasing stimulation at the target location.
  • the transducers can be aimed using piezoelectric devices. Piezoelectric devices allow for minute movements of the transducers in response to electrical signals.
  • ultrasound source 104 is implemented using an array of transducers.
  • the array can be implemented as one or more two-dimensional arrays of transducers.
  • the array can be implemented using a three-dimensional array, such as an array placed upon the skull of a patient.
  • the control 104 can modify various aspects of the transducers.
  • the transducers are similar to those used by the single transducer implementation in that they function to focus the ultrasound waves at a point in space.
  • the array provides a summation of the effects from the transducers in order to further focus ultrasound waves.
  • each transducer can be individually calibrated so as to focus the ultrasound waves at the desired location.
  • Control 104 can then alter the phase of each transducer such that the ultrasound waves provide constructive interference rather than destructive interference so as to increase the effectiveness of the delivered ultrasound energy.
  • the individual transducers of the array of transducers offer little directional or focusing effect when used in isolation. Control 104 modifies the aspects of the ultrasound waves of the array so as to effectively focus the ultrasound waves at the target location.
  • control 104 can use monitoring device 116 to determine the appropriate aspects for the transducer(s).
  • monitoring device 116 may be implemented using, for example, the ExAblate® system (InSightec Ltd. Haifa, Israel). The input from such device provides a determination as to the effectiveness of the current settings of transducer(s).
  • various embodiments of the invention may also be implemented using devices or methods to effectively determine the target location. These implementations can be particularly useful for providing improved accuracy of the ultrasound waves by precisely targeting the desired location.
  • An example of a possible targeting method and system includes the targeting system of the ExAblate ® (InSightec Ltd. Haifa, Israel).
  • the system may be targeted by registering the ultrasound probes to a commercially available user-configurable tool or “universal tool” on a neuronavigation system such as the StealthStation by the Surgical Navigation Technologies division of Medtronic, Inc. (Minneapolis, Minn.).
  • Targeting may also be achieved by affixing ultrasonic transducers to a stereotactic frame, and moving them into correct targeting position via frame-based techniques, such as those used for neurosurgery.
  • the display of the effect at the target may be augmented with a registration and display of calculated or measured temperature at the target site, or a measurement or calculation of neuronal activity at the target site.
  • Temperature displays e.g., obtained from thermal tomography systems, may be derived from measured values or from projected/calculated values. Examples of measurements and display of neuronal activity include multichannel EEG (for example Brain Electrical Activity Monitoring or BEAM) or mangetoencephalography (MEG).
  • FIG. 2A shows the use of two focused-beam ultrasound transducers physiologically suppressing the connection between the two regions by virtue of a mechanism such as long-term depression (LTD).
  • An ultrasound transducer 205 delivers ultrasound energy to neural target 210 via ultrasound vectors 206 .
  • Ultrasound transducer 215 also delivers energy to neural target 220 via ultrasound vectors 216 .
  • Neural target 220 is connected to neural target 210 via neuronal tract 225 .
  • LTD long-term depression
  • LTD long-term depression
  • LTD makes tract 225 less excitable than it would be under normal circumstances. In many instances, such a depressed excitability level is maintained for a period of weeks.
  • LTP may be induced with these focused-beam transducers by changing to a more rapid, regular and strong pulse pattern.
  • FIG. 2B shows the use of an electronically focused ultrasound transducer array to physiologically augment the connection between the two regions by virtue of a mechanism such as LTP, according to an example embodiment of the present invention.
  • Neural target 265 is connected via neural tract 270 , to neural target 260 .
  • Ultrasound transducers 251 , 252 , 253 , 254 and 255 contribute to the total energy delivered to both neural target 260 (via dashed lines 257 ) and to neural target 265 (via solid lines 256 ), by virtue of electronic focusing techniques.
  • Neural target 265 and target 260 are stimulated in a rapid and regular fashion to initiate an LTP process 275 within tract 270 .
  • the target areas are regularly pulsed at a rate of 1 Hz or more, or mildly heated at the same time thereby increasing the neuronal firing rate in tract 270 .
  • This allows for the creating of LTP, or enduring enhancement of the stimulation, along tract 270 .
  • the presence of LTP increases the excitability level of tract 270 relative to normal circumstances. In certain instances, such an increased excitability level can be maintained for a period of weeks.
  • LTD may also be produced with this electronically focused transducer array by changing to a weaker, slow, asynchronous pattern of pulsing.
  • FIG. 3A shows a specific application of the present invention in which LTP is facilitated within the “trisynaptic circuit” of the human hippocampus according to an example embodiment of the present invention.
  • cerebral cortical regions (not shown) have connections 310 to entorhinal cortex 315 .
  • Entorhinal cortex 315 is connected to CA3 field 320 via connection 317 .
  • CA3 field 320 relays signals to CA1 field 325 , via connection 322 .
  • CA1 field 325 relays back to entorhinal cortex 315 via connection 327 .
  • entorhinal cortex 315 relays data back to cerebral cortex regions via connections 310 .
  • long-terra potentiation ( 318 ) is established along connection 317 between entorhinal cortex 315 and CA3 field 320 .
  • the application of stimulation to both entorhinal cortex 315 and CA3 field 320 may improve the speed at which the LTP effect is created and also improve the length that the LTP effect is sustained.
  • FIG. 3B shows the use of the present invention, (in a form similar to that shown in FIG. 2B ) to produce LTP between the entorhinal cortex and the CA3 fields of a human hippocampus, as can be used to augment the encoding of memory.
  • entorhinal cortex 375 is connected to CA3 field 380 (same as 315 and 320 , respectively, in FIG. 3A ).
  • Ultrasound transducers 351 , 352 , 353 and 354 are arranged around a patient's scalp 360 in order to stimulate both the CA3 field 380 (via dashed lines 366 ) and the entorhinal cortex 375 (via solid lines 365 ), by virtue of electronic focusing techniques.
  • a LTP process 318 is initiated within connecting tract 317 as shown in FIG. 3A .
  • FIG. 4A shows the use of two focused-beam ultrasound transducers, each focused upon a different, but connected neural target, according to an example embodiment of the present invention.
  • Transducer 415 and 430 each focuses ultrasound waves 420 and 435 , respectively, to specific points within the brain 410 of patient 400 . More specifically, transducer 415 focuses the ultrasound to target point 427 and transducer 430 focuses the ultrasound at target point 445 .
  • the focus points of the transducers can be controlled by modifying direction of the ultrasound waves 420 and 435 .
  • transducers having different curvatures may be used to provide different depths of convergence.
  • the transducer's position on the skull and distance therefrom can be modified to set the convergence point within the brain 410 .
  • the direction of the ultrasound waves can be modified by controlling the angle of the transducers 415 and 430 relative to brain 410 . This can be accomplished using a variety of approaches.
  • One such approach involves setting the angle using a structure that supports the transducers and allows for adjustment of the angle. The patient's skull can then be immobilized relative to the structure.
  • Another approach involves attaching the transducers directly to the patient's scalp, skull, or by surgically implanting them upon or within the brain itself. The angle may be set accordingly.
  • FIG. 4B shows the use of an array of multiple small ultrasound transducers which may be electronically focused upon one or more targets within a patient's brain by virtue of a coordinated phase and power adjustment to the transducers in the array, according to an example embodiment of the present invention.
  • An array of transducers 470 is attached to patient 450 for the purpose of stimulating brain 460 .
  • Individual control of the transducers is provided through communication connections 480 , which are shown as wires in FIG. 4B . Examples of suitable communications connections include electrical wires, wireless transmissions and optical fibers. In some instances, power is delivered to transducers 470 through the same (or similar) connections.
  • the power, frequency and phase of the transducers can be modified to pinpoint the desired target locations.
  • the delay from the time that the ultrasound wave is first transmitted to the time the ultrasound wave arrives at the target location may vary from transducer to transducer (e.g., due to differences in the location and orientation of the transducers).
  • the distance and type of tissue can directly affect the propagation time of the ultrasound wave.
  • a control device can compensate for differences between the transducers to ensure that the ultrasound waves add to the power of the stimulation at the desired location.
  • one or more of the transducers may not provide any appreciable addition to the amount of stimulation at the target location.
  • one or more of the transducers may create undesirable effects, such as stimulation of areas other than the target locations.
  • the transducer power may be reduced or removed completely.
  • the ineffectiveness of a few of such transducers may be offset by increasing the power of the other transducers or by providing a sufficiently large array of transducers.
  • Other variations are possible including grouping control of a number of transducers together rather than individually controlling each transducer. This may be particularly useful for reducing the complexity of the communications and the complexity of various control parameters.
  • the transducers can be used to stimulate two different target areas in a synchronous or asynchronous manner to produce LTP or LTD, respectively, between the different target areas.
  • the invention need not be limited to only two target areas. For instance, three or more areas of the brain may be stimulated for the purposes of facilitating LTP or LTD therebetween. In another instance, a number of different target areas may be sequentially stimulated to produce an LTP communication pathway of related target areas. Similarly, a sequence of different target areas may be stimulated to disrupt a communication pathway by producing LTD between the sequential target areas. Various combinations thereof are also possible.
  • the thermal properties of sound waves are supplemented with electrical impulses generated by implanted devices that respond to mechanical motion produced by the sound waves.
  • a device implanted surgically in proximity to a group of neurons that one wishes to affect, electrically stimulates those neurons when in receipt of sound waves.
  • implanted piezoelectric antennas are surgically implanted adjacent to the neural structure that is the target of the modulation.
  • Such antennae produce electrical current via the piezoelectric effect of an implanted piezoelectric generator, which is rapidly moved back and forth by externally applied ultrasound.
  • the electric current from the piezoelectric generator serves to stimulate neurons electrically, in response to the externally applied ultrasonic waves. All other principles of synchrony and asynchrony as they apply to the induction of LTP and LTD, respectively, still hold under this paradigm.
  • the implanted ultrasound-to-electrical current conversion device serves to enhance the same processes as previously described herein.
  • implantable devices can be implemented as the primary source of stimulation (e.g., with minimal thermal heating).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)

Abstract

One embodiment involves modifying neural transmission patterns between neural structures and/or neural regions in a noninvasive manner. In a related exemplary method, sound waves are directed toward a first targeted neural structure and characteristics of the sound waves are controlled at the first target neural structure with respect to characteristics of sound waves at the second target neural structure. In response, neural transmission patterns modified to produce the intended effect (e.g., long-term potentiation and long-term depression of the neural transmission patterns). In a related embodiment, a transducer produces the sound for stimulating the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the sound waves as described above to modify the neural transmission patterns between the first and second neural structures.

Description

    RELATED PATENT DOCUMENTS
  • This is a conversion of U.S. Provisional Patent Application Ser. No. 60/984,225, entitled “Device and Method for Non-Invasive Neuromodulation,” and filed on Oct. 31, 2007, to which benefit is claimed under 35 U.S.C. § 119.
  • FIELD OF THE INVENTION
  • The present invention relates generally to systems and approaches for stimulation of neural circuits and more particularly to facilitating long-term potentiation or long-term depression between neural circuits.
  • BACKGROUND
  • Long-term potentiation (LTP) involves the process of establishing an association between the firing of two cells or groups of cells. For instance, Hebb's rule essentially states that if an axon of cell A is near enough to excite a cell B and repeatedly or persistently takes part in firing cell B, an increase in the strength of the chemical synapse between the cells takes place such that A′s efficiency, as one of the cells firing B, is increased. LTP has been shown to last from minutes to several months. Conditions for establishing LTP are favorable when a pre-synaptic neuron and a post-synaptic neuron are both depolarized in a synchronous manner. An opposite effect, long-term depression (LTD), has also been established. LTD is the weakening of a neuronal synapse that lasts from hours to months. In the cerebellar Purkinje cells, LTD results from strong synaptic stimulation. By contrast, in the hippocampus, LTD results from persistent weak synaptic stimulation, or when a pre-synaptic neuron and a postsynaptic neuron discharge in an asynchronous manner. Since the establishment of Hebb's original rule, additional “Hebb's Rules” have been proposed for the prediction of self-organization of neuronal systems, and these rules appear to govern the process by which the brain is effectively sculpted over time in order to master the demands of the environment.
  • Neurons and other electrically excitable cells (including cardiac cells and some endocrine cells) have spontaneous firing rates: they discharge action potentials at a baseline rate, in the absence of external stimulation or suppression. This spontaneous firing rate is affected by temperature. Generally, the warmer an electrically excitable cell, the faster the spontaneous firing rate, and the colder the cell, the slower the firing rate. When cells become extremely warm, such as in a very high fever, they have a high propensity to fire. At extremes, such an increase in firing rates may manifest as a risk of a febrile seizure.
  • Neuromodulation is the control of nerve activity, and is usually implemented for the purpose of treating disease. In the strictest sense, neuromodulation may be accomplished with a surgical intervention like cutting an aberrant nerve tract. However, the semi-permanent nature of a surgical procedure leaves little room for later adjustment and optimization. Likewise, it could be asserted that neuromodulation can be accomplished with chemical agents or medications. Chemical agents or medications may be undesirable because, for example, many medications are difficult to deliver to specific anatomy, and because the titration (increasing or decreasing the dose of a medication) is a slow and imprecise way to achieve a desired effect on a specific target. Consequently, the term neuromodulation usually implies the use of energy-delivering devices.
  • Several categories of device-based neuromodulation methods are known in the art. These include electrical neuromodulation, magnetic neuromodulation and opto-genetic neuromodulation.
  • Electrical nerve stimulation is well-established. Examples of electrical approaches include transcutaneous electrical nerve stimulation (TENS) units, and the surgically implanted electrodes of deep brain stimulation (DBS). TENS units are used to lessen superficial nerve pain within skin and muscle. Because the device is non-invasive and has a low power output, its use involves little risk. However, the efficacy of TENS is limited to nerve distributions very close to the surface. Additionally, TENS has little focusing ability for targeting with close tolerances. Moreover, its therapeutic use shows a fairly small effective treatment area. DBS is a useful approach for treating conditions including Parkinson's disease, essential tremor, epilepsy, chronic pain, depression and obsessive-compulsive disorder. In the case of Parkinson's disease, a multi-contact electrode may be neurosurgically implanted in the subthalamic nucleus of a patient. Once connected to a pulse generation unit similar to a cardiac pacemaker device, the electrodes may be electrically pulsed at various rates, effectively driving the activity of the neurons immediately adjacent to the electrode contacts, using currents of about 3 amps and voltages between 1 and 10. Subsequently, various configurations of electrode pairs or monopolar configurations may be empirically tested on the patient for effect and tolerability. At a later time, the circuit configuration or pulse parameters may be changed by the physician in charge, usually without the need to physically disturb the implanted electrode. One disadvantage of DBS is that, by definition, it requires a highly invasive and risky neurosurgical implantation procedure. If the site of implantation is later deemed suboptimal, or if the device physically fails, more surgery is required.
  • Magnetic stimulation involves the discharge of large capacitors into an electrically conductive coil placed external to a patient's brain or body. As electrical current runs through the coil, a magnetic field is induced, which in turn, induces an electric field in nerve membranes and surrounding fluid. This forces nerves to depolarize with each discharge of the capacitors in the machine. Magnetic stimulation, when delivered at rates of 5-20 Hz, tend to be stimulating to nerves that it affects, for some time after the magnetic pulse delivery has stopped. Pulse rates of less than 1 Hz tend to suppress the activity of affected nerves after stimulation has ended. Very fast pulse trains (e.g., 50 Hz), punctuated by absence of pulses 6-9 times per second (“theta rhythm”) also tend to suppress the activity of affected neurons. Magnetic neuromodulation, in the form of repetitive transcranial magnetic stimulation, is useful for the treatment of depression, and likely several other neurological and psychiatric conditions. The derived effects may last from minutes to months after the end of magnetic treatment. One limitation of magnetic neuromodulation is the difficulty in achieving tight focus of the effect, since magnetic fields capable of penetrating to useful depth tend to be large in footprint, as dictated by the Biot-Savart Law.
  • Opto-genetic neuromodulation is a newly discovered approach which has the advantages of being neuron-type specific. Using this approach, light-sensitive ion channels or pumps are genetically transferred to the targeted neurons of the brain to be stimulated. A flashing light from an implanted device provides a signal to these channels or pumps to activate. This leads to either neuronal depolarization, or neuronal hyperpolarization, depending upon the nature of the light-sensitive channel or pump. Opto-genetic approaches lend themselves to both neuronal up-regulation and down-regulation. Disadvantages include the requirement of implanted hardware, and the need for the genetic modification of targeted neurons.
  • Ultrasound is mechanical vibration at frequencies above the range of human hearing, or above 16 kHz. Most medical uses for ultrasound use frequencies in the range of 1 to 20 MHz. Low to medium intensity ultrasound products are widely used by physicians, nurses, physical therapists, masseurs and athletic trainers. The most common applications are probably wanning stiff, swollen or painful joints or muscles in a manner similar to a hot compress, but with better penetration. Many ultrasound products have been commercially available for years, including consumer-grade massage machines. By design, the power on these devices is designed to be too low to warm or otherwise affect structures more than two centimeters or so below the surface. Also, these devices are not capable of tight focus at depth, nor are there means for accurately aiming such devices toward precise structural coordinates within the body. As ultrasound of sufficient strength can cause pain in peripheral nerves with each pulse, it is likely that mechanical perturbations caused by ultrasound can cause nerves to discharge.
  • SUMMARY OF THE INVENTION
  • Various aspects of the present invention are directed to addressing the above issues and/or generally advancing technology in the above-discussed contexts and other contexts.
  • In accordance with one embodiment, the present invention is directed to methods, devices and systems that are used to modify neural transmission patterns between neural structures and/or regions. Consistent herewith, one exemplary method involves directing sound waves toward a first targeted neural structure, controlling characteristics of the sound waves at the first target neural structure with respect to characteristics of sound waves at the second target neural structure, and in response, modifying neural transmission patterns. In a related embodiment, a transducer produces the sound for stimulating the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the sound waves as described above to modify the neural transmission patterns between the first and second neural structures.
  • In accordance with one embodiment, the present invention is directed to methods, devices and systems that are used to modify neural transmission patterns between neural structures and/or regions. Consistent herewith, one exemplary method involves directing stimuli toward a first targeted neural structure, controlling characteristics of the stimulus at the first target neural structure with respect to characteristics of stimulus at the second target neural structure, and in response, modifying neural transmission patterns. In a related embodiment, a transducer produces the stimulus for the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the stimulus as described above to modify the neural transmission patterns between the first and second neural structures.
  • As discussed with the detailed description that follows, more specific embodiments of the present invention concern various levels of detail for controlling the neural-transmission modulation.
  • The above summary of the present invention is not intended to describe each illustrated embodiment or every implementation of the present invention. The figures in the detailed description that follow more particularly exemplify these embodiments.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention may be more completely understood in consideration of the detailed description of various embodiments of the invention that follows in connection with the accompanying drawings, in which:
  • FIG. 1 shows a system for altering neural patterns between two groups of cells, according to an example embodiment of the present invention;
  • FIG. 2A shows the use of two focused-beam ultrasound transducers physiologically suppressing the connection between two regions, according to an example embodiment of the present invention;
  • FIG. 2B shows the use of an electronically focused ultrasound transducer array to physiologically augment the connection between two regions, according to an example embodiment of the present invention;
  • FIG. 3A shows a specific application of the present invention in which LTP is facilitated within the “trisynaptic circuit” of the human hippocampus, according to an example embodiment of the present invention;
  • FIG. 3B shows the use of the present invention, to produce LTP between the entorhinal cortex and the CA3 fields of a human hippocampus, as can be used to augment the encoding of memory, according to an example embodiment of the present invention;
  • FIG. 4A shows the use of two focused-beam ultrasound transducers, each focused upon a different, but connected neural target, according to an example embodiment of the present invention; and
  • FIG. 4B shows an array of multiple small ultrasound transducers which may be electronically directed at one or more target regions within a patient's brain via a coordinated phase and power adjustment, also according to the present invention.
  • While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
  • DETAILED DESCRIPTION
  • The present invention is believed to be useful for enabling practical application of a variety of LTP and LTD systems, and the invention has been found to be particularly suited for use in systems and methods dealing with generating LTP or LTD effects in neural circuits through the use of sounds waves (which may include high-intensity focused ultrasound), radio frequency (RF) transmissions, electrical current, magnetic fields or ionizing radiation. In the context of this invention, the terms “sound” and “ultrasound” are used interchangeably. For simplicity, while the present invention is not necessarily limited to such applications, various aspects of the invention may be appreciated through a discussion of various examples using this context.
  • Various embodiments of the present invention are directed toward the use of ultrasound to produce LTP or LTD within a living subject. Sound waves are used to stimulate a first portion of neurons. For LTP, the sound waves are used to concurrently stimulate a second portion of neurons in a synchronous manner. For LTD, the sound waves are used to stimulate a second portion of neurons in an asynchronous manner. Sound waves provide stimulation both in terms of thermal properties and mechanical jarring. While specific embodiments and applications thereof involve sound waves being in the ultrasound frequency range, they need not be so limited. For example, aspects of the present invention can employ frequencies that are outside of the ultrasound frequency range.
  • In accordance with one embodiment, the present invention is directed to a method for modifying neural transmission patterns between neural structures. The method involves producing and directing sound waves or RF transmissions toward a first targeted neural structure, controlling characteristics of the sound waves or RF transmissions at the first target neural structure with respect to characteristics of sound waves or RF transmissions at the second target neural structure, and thereby modifying neural transmission patterns. In a related embodiment, a transducer produces the sound for stimulating the first neural structure and the second neural structure, and an electronically-based control circuit is used to control characteristics of the sound waves as described above to modify the neural transmission patterns between the first and second neural structures. In another related embodiment, a RF transmitter is used to produce RF transmissions and to focus the transmissions toward a first target neural structure.
  • In a more specific embodiment, the present invention uses High-intensity Focused Ultrasound (HIFU) as a powerful ultrasound emitter. In connection herewith, ultrasound waves are aimed and focused at a targeted depth geometrically, for example, by using a lens at the emitting end, or by using a curved transducer portion (e.g., a partial sphere). Ultrasound may also be aimed and focused electronically, by coordinating the phase and intensity of individual transducer elements within an array, thereby steering the location of greatest intensity, and even correcting for transmission distortions created, for example by inhomogeneities in the skull. As an ultrasound wave travels through tissue, the mechanical excitation of the tissue generates heat. Thus, the focal point of a HIFU system may be heated substantially in response to the ultrasound. Excessive heat may cause cell damage or even cell death. The threshold for cell death is generally bringing the targeted tissue to 56 degrees Celsius for one second, or 52 degrees Celsius for a longer period of time. Also, tissues held above 43 degrees Celsius for more than an hour or so may have their physiological processes (including cell division) interrupted. Accordingly, to change the firing patterns of targeted neurons, the temperature can be raised to a more moderate temperature above the normal 37 degrees Celsius. In another example, the targeted neurons may be raised to 40-42 degrees Celsius for repeated, brief periods of time, resulting in an increased spontaneous firing rate, and enabling one step of the LTP/LTD induction process.
  • For further information on the use of such HIFU, and related systems, reference may be made to various literature including, for example, U.S. Pat. No. 4,616,231, filed on Mar. 26, 1984 to Autrey et al. and entitled “Narrow-band beam steering system,” U.S. Pat. No. 4,865,042, filed on Aug. 8, 1986 to Umemura et al. and entitled “Ultrasonic irradiation system,” U.S. Pat. No. 5,520,188, filed on Nov. 2, 1994 to Hennige et al. and entitled “Annular array transducer,” U.S. Pat. No. 7,175,596 filed on Oct. 29, 2001 to Vitek et al. and entitled “System and method for sensing and locating disturbances in an energy path of a focused ultrasound system,” U.S. Pat. No. 6,805,129 filed on Oct. 27, 2000 to Pless et al. and entitled “Apparatus and method for ablating tissue,” and U.S. Pat. No. 6,506,154 filed on Nov. 28, 2000 to Ezion et al. and entitled “Systems and methods for controlling a phased array focused ultrasound system,” each of which is fully incorporated herein by reference. An MRI guided approach to beam aiming with improved phase adjustment focusing techniques incorporates stereotactic capabilities into HIFU. Some of the focused ultrasound systems have shown effectiveness for accurately targeting small lesions within the brain, thermally destroying the targeted tissue, and leaving surrounding tissue unharmed. A few devices allow for the destruction of brain tumors in a non-invasive manner (i.e., through an intact skull).
  • According to yet another embodiment of the present invention, HIFU is used to stimulate two different areas of the brain. The stimulation of each area is coordinated in order to facilitate the development of either LTP or LTD between the two different areas of the brain. For example, each of the areas can be stimulated in a synchronous fashion to produce LTP. If the stimulation results in an increased rate of depolarization of the neurons, the probability that both areas of the brain will fire at the same time is likewise increased. Moreover, LTP may be developed where the stimulation results in one of the areas generating action potentials more readily in response to stimulus from the other area (e.g., by having a lower depolarization threshold). In order to produce LTD, the areas may be stimulated in an asynchronous fashion to produce an increased probability of the different areas firing independently from one another.
  • In accordance with the present invention, it has been discovered that not all neurons react in the same fashion to temperature variations. For instance, some neurons increase their firing rate in response to a decrease in temperature and such a response impacts expected efforts in developing LTP or LTD. According to certain embodiments of the present invention, temperature data regarding these neuron-regions are used in developing LTP or LTD between the areas of the brain. In a particular instance, an area of the brain containing neurons that increase their rate of fire due to the stimulation is targeted, and at the same time, another area of the brain containing neurons that decrease their rate of fire due to stimulation is also targeted. This may be particularly useful for facilitating LTD between the targeted areas.
  • For further information on the use of RF transmitters to elevate temperatures of target cells, reference can be made to Kato H., Ishida T. “Present and future status of noninvasive selective deep heating using RF in hyperthermia” Med Biol Eng Comput. 1993 Jul.; 31 Suppl:S2-11 and to Gelvich E A, Mazokhin V N “Contact flexible microstrip applicators (CFMA) in a range from microwaves up to short waves” IEEE Trans Biomed Eng. 2002 Sept.; 49(9):1015-23), which are fully incorporated herein by reference. For simplicity, much of the discussion is limited to ultrasound energy; however, the invention is not so limited. For instance, it should be apparent that for many applications the use of RF frequency energy could be used in place of ultrasound energy. Whether by ultrasound, radio frequency energy, or other stimuli, neural effects of the delivered stimulus may be produced by induced temperature alteration, electrical stimulation, or by mechanical perturbation.
  • FIG. 1 shows a system for altering neural patterns between two groups of cells, according to an example embodiment of the present invention. Ultrasound (or RF) source 104 focuses the ultrasound (or RF) 106, 108 at locations 110 and 114. In some instances, the ultrasound can be focused at only one of the locations, or at one location at a time (e.g., for developing LTD). Control 102 controls the ultrasound produced by ultrasound source 104. In a particular instance, control 102 is responsive to input from monitor device 116. The stimulation from sound (or RF) 106, 108 can be used to effect (e.g., facilitate or frustrate through LTP or LTD) a pathway 112 between locations 110 and 114.
  • Ultrasound source 104 can be implemented using a number of different techniques and mechanisms. According to one embodiment, ultrasound source 104 is implemented using one single transducer for each of location 110 and 114. Such a transducer acts as a lens to focus the ultrasound waves at a point in space. The control 104 can modify various aspects of the transducer including, but not limited to, direction of focus, distance from the target location, strength of the ultrasound waves or the frequency of the ultrasound waves. Such aspects allow for precise aiming of the focal point of the ultrasound waves. This can be particularly useful for reducing unintended stimulation of cells while increasing stimulation at the target location. In some instances, the transducers can be aimed using piezoelectric devices. Piezoelectric devices allow for minute movements of the transducers in response to electrical signals.
  • According to another embodiment, ultrasound source 104 is implemented using an array of transducers. In one instance, the array can be implemented as one or more two-dimensional arrays of transducers. In another instance, the array can be implemented using a three-dimensional array, such as an array placed upon the skull of a patient. Similar to the single transducer implementation, the control 104 can modify various aspects of the transducers. In one instance, the transducers are similar to those used by the single transducer implementation in that they function to focus the ultrasound waves at a point in space. The array provides a summation of the effects from the transducers in order to further focus ultrasound waves. In one instance, each transducer can be individually calibrated so as to focus the ultrasound waves at the desired location. Control 104 can then alter the phase of each transducer such that the ultrasound waves provide constructive interference rather than destructive interference so as to increase the effectiveness of the delivered ultrasound energy. In another instance, the individual transducers of the array of transducers offer little directional or focusing effect when used in isolation. Control 104 modifies the aspects of the ultrasound waves of the array so as to effectively focus the ultrasound waves at the target location.
  • In various embodiments of the invention, control 104 can use monitoring device 116 to determine the appropriate aspects for the transducer(s). For instance, monitoring device 116 may be implemented using, for example, the ExAblate® system (InSightec Ltd. Haifa, Israel). The input from such device provides a determination as to the effectiveness of the current settings of transducer(s).
  • Although not shown, various embodiments of the invention may also be implemented using devices or methods to effectively determine the target location. These implementations can be particularly useful for providing improved accuracy of the ultrasound waves by precisely targeting the desired location. An example of a possible targeting method and system includes the targeting system of the ExAblate ® (InSightec Ltd. Haifa, Israel). Alternatively, the system may be targeted by registering the ultrasound probes to a commercially available user-configurable tool or “universal tool” on a neuronavigation system such as the StealthStation by the Surgical Navigation Technologies division of Medtronic, Inc. (Minneapolis, Minn.). Targeting may also be achieved by affixing ultrasonic transducers to a stereotactic frame, and moving them into correct targeting position via frame-based techniques, such as those used for neurosurgery.
  • The display of the effect at the target may be augmented with a registration and display of calculated or measured temperature at the target site, or a measurement or calculation of neuronal activity at the target site. Temperature displays, e.g., obtained from thermal tomography systems, may be derived from measured values or from projected/calculated values. Examples of measurements and display of neuronal activity include multichannel EEG (for example Brain Electrical Activity Monitoring or BEAM) or mangetoencephalography (MEG).
  • FIG. 2A shows the use of two focused-beam ultrasound transducers physiologically suppressing the connection between the two regions by virtue of a mechanism such as long-term depression (LTD). An ultrasound transducer 205 delivers ultrasound energy to neural target 210 via ultrasound vectors 206. Ultrasound transducer 215 also delivers energy to neural target 220 via ultrasound vectors 216. Neural target 220 is connected to neural target 210 via neuronal tract 225. As target 220 and target 210 are stimulated in a slow-pulse rate, asynchronous fashion, long-term depression (LTD) process 226 is initiated within tract 225. The presence of LTD makes tract 225 less excitable than it would be under normal circumstances. In many instances, such a depressed excitability level is maintained for a period of weeks. Conversely, LTP may be induced with these focused-beam transducers by changing to a more rapid, regular and strong pulse pattern.
  • FIG. 2B shows the use of an electronically focused ultrasound transducer array to physiologically augment the connection between the two regions by virtue of a mechanism such as LTP, according to an example embodiment of the present invention. Neural target 265 is connected via neural tract 270, to neural target 260. Ultrasound transducers 251, 252, 253, 254 and 255 contribute to the total energy delivered to both neural target 260 (via dashed lines 257) and to neural target 265 (via solid lines 256), by virtue of electronic focusing techniques. Neural target 265 and target 260 are stimulated in a rapid and regular fashion to initiate an LTP process 275 within tract 270. In a specific example, the target areas are regularly pulsed at a rate of 1 Hz or more, or mildly heated at the same time thereby increasing the neuronal firing rate in tract 270. This allows for the creating of LTP, or enduring enhancement of the stimulation, along tract 270. The presence of LTP increases the excitability level of tract 270 relative to normal circumstances. In certain instances, such an increased excitability level can be maintained for a period of weeks. Conversely, LTD may also be produced with this electronically focused transducer array by changing to a weaker, slow, asynchronous pattern of pulsing.
  • FIG. 3A shows a specific application of the present invention in which LTP is facilitated within the “trisynaptic circuit” of the human hippocampus according to an example embodiment of the present invention. In the trisynaptic circuit, cerebral cortical regions (not shown) have connections 310 to entorhinal cortex 315. Entorhinal cortex 315 is connected to CA3 field 320 via connection 317. CA3 field 320 relays signals to CA1 field 325, via connection 322. CA1 field 325 relays back to entorhinal cortex 315 via connection 327. Finally, entorhinal cortex 315 relays data back to cerebral cortex regions via connections 310. When rapid and strong stimulations are applied to entorhinal cortex 315, long-terra potentiation (318) is established along connection 317 between entorhinal cortex 315 and CA3 field 320. Moreover, it is believed that the application of stimulation to both entorhinal cortex 315 and CA3 field 320 may improve the speed at which the LTP effect is created and also improve the length that the LTP effect is sustained.
  • FIG. 3B shows the use of the present invention, (in a form similar to that shown in FIG. 2B) to produce LTP between the entorhinal cortex and the CA3 fields of a human hippocampus, as can be used to augment the encoding of memory. Specifically, entorhinal cortex 375 is connected to CA3 field 380 (same as 315 and 320, respectively, in FIG. 3A). Ultrasound transducers 351, 352, 353 and 354 are arranged around a patient's scalp 360 in order to stimulate both the CA3 field 380 (via dashed lines 366) and the entorhinal cortex 375 (via solid lines 365), by virtue of electronic focusing techniques. By stimulating the entorhinal cortex 375 and CA3 field 380 in a rapid and regular fashion, a LTP process 318 is initiated within connecting tract 317 as shown in FIG. 3A.
  • FIG. 4A shows the use of two focused-beam ultrasound transducers, each focused upon a different, but connected neural target, according to an example embodiment of the present invention. Transducer 415 and 430 each focuses ultrasound waves 420 and 435, respectively, to specific points within the brain 410 of patient 400. More specifically, transducer 415 focuses the ultrasound to target point 427 and transducer 430 focuses the ultrasound at target point 445.
  • The focus points of the transducers can be controlled by modifying direction of the ultrasound waves 420 and 435. For instance, transducers having different curvatures may be used to provide different depths of convergence. Likewise, the transducer's position on the skull and distance therefrom can be modified to set the convergence point within the brain 410. The direction of the ultrasound waves can be modified by controlling the angle of the transducers 415 and 430 relative to brain 410. This can be accomplished using a variety of approaches. One such approach involves setting the angle using a structure that supports the transducers and allows for adjustment of the angle. The patient's skull can then be immobilized relative to the structure. Another approach involves attaching the transducers directly to the patient's scalp, skull, or by surgically implanting them upon or within the brain itself. The angle may be set accordingly.
  • FIG. 4B shows the use of an array of multiple small ultrasound transducers which may be electronically focused upon one or more targets within a patient's brain by virtue of a coordinated phase and power adjustment to the transducers in the array, according to an example embodiment of the present invention. An array of transducers 470 is attached to patient 450 for the purpose of stimulating brain 460. Individual control of the transducers is provided through communication connections 480, which are shown as wires in FIG. 4B. Examples of suitable communications connections include electrical wires, wireless transmissions and optical fibers. In some instances, power is delivered to transducers 470 through the same (or similar) connections.
  • According to one embodiment of the invention, the power, frequency and phase of the transducers can be modified to pinpoint the desired target locations. The delay from the time that the ultrasound wave is first transmitted to the time the ultrasound wave arrives at the target location may vary from transducer to transducer (e.g., due to differences in the location and orientation of the transducers). For instance, the distance and type of tissue can directly affect the propagation time of the ultrasound wave. A control device can compensate for differences between the transducers to ensure that the ultrasound waves add to the power of the stimulation at the desired location. In some instances, one or more of the transducers may not provide any appreciable addition to the amount of stimulation at the target location. In other instances, one or more of the transducers may create undesirable effects, such as stimulation of areas other than the target locations. For such instances, the transducer power may be reduced or removed completely. The ineffectiveness of a few of such transducers may be offset by increasing the power of the other transducers or by providing a sufficiently large array of transducers. Other variations are possible including grouping control of a number of transducers together rather than individually controlling each transducer. This may be particularly useful for reducing the complexity of the communications and the complexity of various control parameters.
  • Once the selected phase, frequency and other constraints are set, the transducers can be used to stimulate two different target areas in a synchronous or asynchronous manner to produce LTP or LTD, respectively, between the different target areas. The invention need not be limited to only two target areas. For instance, three or more areas of the brain may be stimulated for the purposes of facilitating LTP or LTD therebetween. In another instance, a number of different target areas may be sequentially stimulated to produce an LTP communication pathway of related target areas. Similarly, a sequence of different target areas may be stimulated to disrupt a communication pathway by producing LTD between the sequential target areas. Various combinations thereof are also possible.
  • In conjunction with a specific embodiment of the present invention, the thermal properties of sound waves are supplemented with electrical impulses generated by implanted devices that respond to mechanical motion produced by the sound waves. For instance a device, implanted surgically in proximity to a group of neurons that one wishes to affect, electrically stimulates those neurons when in receipt of sound waves.
  • In one such embodiment, implanted piezoelectric antennas are surgically implanted adjacent to the neural structure that is the target of the modulation. Such antennae produce electrical current via the piezoelectric effect of an implanted piezoelectric generator, which is rapidly moved back and forth by externally applied ultrasound. The electric current from the piezoelectric generator serves to stimulate neurons electrically, in response to the externally applied ultrasonic waves. All other principles of synchrony and asynchrony as they apply to the induction of LTP and LTD, respectively, still hold under this paradigm. The implanted ultrasound-to-electrical current conversion device serves to enhance the same processes as previously described herein. For further information regarding implanted piezoelectric antennas, reference may be made to recent publications including, for example, Wang X, Song J, Liu J, Wang Z L, in Direct-current Nanogenerator Driven By Ultrasonic Waves, Science, 2007, Apr. 6-316(5821):102-5, which is fully incorporated herein by reference.
  • In another embodiment of the present invention, such implantable devices can be implemented as the primary source of stimulation (e.g., with minimal thermal heating).
  • The various embodiments described above are provided by way of illustration only and should not be construed to limit the invention. Based on the above discussion and illustrations, those skilled in the art will readily recognize that various modifications and changes may be made to the present invention without strictly following the exemplary embodiments and applications illustrated and described herein. For instance, such changes may include variations in the duration and frequency of the stimulation between target areas. Such modifications and changes do not depart from the true spirit and scope of the present invention, which is set forth in the following claims.

Claims (19)

1. A system for modifying neural transmission patterns between a first neural structure and a second neural structure, the system comprising:
a transducer arrangement configured and arranged to produce sound for stimulating the first neural structure and the second neural structure;
a control circuit configured and arranged to control of characteristics of sound waves at the first target neural structure with respect to characteristics of sound waves at the second target neural structure for modifying the neural transmission patterns between a first neural structure and a second neural structure; and
implanted piezoelectric antennas configured to produce an electrical current in response to the sound waves.
2. The system of claim 1, wherein modifying the neural transmission patterns includes one of long-term potentiation and long-term depression of the neural transmission patterns.
3. The system of claim 1, wherein the sound waves at first target neural structure sufficiently raise the temperature of the first target neural structure so as to affect the firing rate of neurons in the first target neural structure.
4. The system of claim 1, wherein the transducer arrangement includes a plurality of transducers that are each configured and arranged to be controlled by the control circuit.
5. A method for modifying neural transmission patterns between a first neural structure and a second neural structure, the method comprising:
producing sound waves;
directing the sound waves to implanted piezoelectric antennas configured to produce an electrical current in response to the sound waves at a first target neural structure and a second target neural structure; and
controlling characteristics of sound waves at the first target neural structure with respect to characteristics of sound waves at the second target neural structure to modify neural transmission patterns.
6. A device for neuromodulation comprising:
one or more energy emitters configured and arranged to emit energy that is focused to a focal point;
a targeting controller configured and arranged to determine a location in space at which the focal point is desired; and
an aiming controller configured and arranged to direct the focal point toward the location in space to non-destructively alter a pattern of functional responsiveness of cells at the location in space for a first time period to change responsiveness between two groups of cells for a second period of time that is substantially greater than the first period of time.
7. The device of claim 6, further including a secondary group of one or more energy emitters, wherein each of the two groups of cells is stimulated by one of the energy emitters.
8. The device of claim 6, wherein the responsiveness between two groups of cells includes neural connectivity.
9. The device of claim 6, wherein the responsiveness between two groups of cells is moderated by long-term potentiation (LTP).
10. The device of claim 6, wherein the responsiveness between two groups of cells is moderated by long-term depression (LTD).
11. The device of claim 6, wherein the energy heats a first group of cells of the two groups of cells thereby changing a spontaneous firing rate of the first group of cells.
12. The device of claim 6, wherein the altering of a pattern of functional responsiveness is due to mechanical perturbations of a cell from the energy.
13. The device of claim 6, wherein the energy is focused using one of a lens and a curved transducer portion.
14. The device of claim 6, wherein the energy is focused by aiming an array of the energy emitters at the focal point.
15. A system for modifying neural transmission patterns between a first neural structure and a second neural structure, the system comprising:
a transducer arrangement configured and arranged to wirelessly stimulate the first neural structure and the second neural structure;
a control circuit configured and arranged to control of characteristics of the stimulus at the first target neural structure with respect to characteristics of sound waves at the second target neural structure thereby modifying the neural transmission patterns between a first neural structure and a second neural structure; and
an implanted piezoelectric antenna configured to produce an electrical current in response to the sound waves.
16. The system of claim 15 wherein the transducer arrangement produces ultrasound for stimulating the first neural structure and the second neural structure.
17. The system of claim 15 wherein the transducer arrangement produces radio frequency energy for stimulating the first neural structure and the second neural structure.
18. The system of claim 15 wherein the transducer arrangement produces a magnetic field for stimulating the first neural structure and the second neural structure.
19. The system of claim 15 wherein the transducer arrangement produces ionizing radiation for stimulating the first neural structure and the second neural structure.
US16/037,974 2007-10-31 2018-07-17 Device And Method for Non-Invasive Neuromodulation Abandoned US20190022425A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/037,974 US20190022425A1 (en) 2007-10-31 2018-07-17 Device And Method for Non-Invasive Neuromodulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98422507P 2007-10-31 2007-10-31
US12/263,026 US10035027B2 (en) 2007-10-31 2008-10-31 Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US16/037,974 US20190022425A1 (en) 2007-10-31 2018-07-17 Device And Method for Non-Invasive Neuromodulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/263,026 Continuation US10035027B2 (en) 2007-10-31 2008-10-31 Device and method for ultrasonic neuromodulation via stereotactic frame based technique

Publications (1)

Publication Number Publication Date
US20190022425A1 true US20190022425A1 (en) 2019-01-24

Family

ID=40583766

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/263,026 Active 2030-06-16 US10035027B2 (en) 2007-10-31 2008-10-31 Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US16/037,974 Abandoned US20190022425A1 (en) 2007-10-31 2018-07-17 Device And Method for Non-Invasive Neuromodulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/263,026 Active 2030-06-16 US10035027B2 (en) 2007-10-31 2008-10-31 Device and method for ultrasonic neuromodulation via stereotactic frame based technique

Country Status (1)

Country Link
US (2) US10035027B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034018A2 (en) 1999-10-25 2001-05-17 Therus Corporation Use of focused ultrasound for vascular sealing
US6626855B1 (en) 1999-11-26 2003-09-30 Therus Corpoation Controlled high efficiency lesion formation using high intensity ultrasound
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US9238150B2 (en) * 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
US10052497B2 (en) * 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8926959B2 (en) * 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US20070233185A1 (en) 2005-10-20 2007-10-04 Thomas Anderson Systems and methods for sealing a vascular opening
US9352167B2 (en) 2006-05-05 2016-05-31 Rio Grande Neurosciences, Inc. Enhanced spatial summation for deep-brain transcranial magnetic stimulation
US8267850B2 (en) * 2007-11-27 2012-09-18 Cervel Neurotech, Inc. Transcranial magnet stimulation of deep brain targets
US20080071315A1 (en) * 2006-08-31 2008-03-20 Tamara Colette Baynham Integrated catheter and pulse generator systems and methods
US8398692B2 (en) * 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) * 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US8956273B2 (en) * 2007-08-20 2015-02-17 Cervel Neurotech, Inc. Firing patterns for deep brain transcranial magnetic stimulation
US8956274B2 (en) * 2007-08-05 2015-02-17 Cervel Neurotech, Inc. Transcranial magnetic stimulation field shaping
US20100185042A1 (en) * 2007-08-05 2010-07-22 Schneider M Bret Control and coordination of transcranial magnetic stimulation electromagnets for modulation of deep brain targets
WO2009055634A1 (en) * 2007-10-24 2009-04-30 Neostim Inc. Intra-session control of transcranial magnetic stimulation
US20100331602A1 (en) * 2007-09-09 2010-12-30 Mishelevich David J Focused magnetic fields
US8265910B2 (en) * 2007-10-09 2012-09-11 Cervel Neurotech, Inc. Display of modeled magnetic fields
US20100286468A1 (en) * 2007-10-26 2010-11-11 David J Mishelevich Transcranial magnetic stimulation with protection of magnet-adjacent structures
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US20090149782A1 (en) * 2007-12-11 2009-06-11 Donald Cohen Non-Invasive Neural Stimulation
ES2608498T3 (en) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
EP2294208B1 (en) * 2008-05-29 2013-05-08 The Board of Trustees of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
CA2728238C (en) * 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
CA2728402A1 (en) * 2008-06-17 2009-12-23 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
EP2821103B1 (en) * 2008-07-14 2019-05-15 Arizona Board Regents For And On Behalf Of Arizona State University Devices for modulating cellular activity using ultrasound
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
GB0821325D0 (en) * 2008-11-21 2008-12-31 Ucl Business Plc Method and apparatus for performing deep brain stimulation with an electric field
US8795148B2 (en) * 2009-10-26 2014-08-05 Cervel Neurotech, Inc. Sub-motor-threshold stimulation of deep brain targets using transcranial magnetic stimulation
US8723628B2 (en) 2009-01-07 2014-05-13 Cervel Neurotech, Inc. Shaped coils for transcranial magnetic stimulation
US8517962B2 (en) 2009-10-12 2013-08-27 Kona Medical, Inc. Energetic modulation of nerves
US8986231B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
US9174065B2 (en) 2009-10-12 2015-11-03 Kona Medical, Inc. Energetic modulation of nerves
US20110118600A1 (en) 2009-11-16 2011-05-19 Michael Gertner External Autonomic Modulation
US20110092880A1 (en) 2009-10-12 2011-04-21 Michael Gertner Energetic modulation of nerves
US8469904B2 (en) 2009-10-12 2013-06-25 Kona Medical, Inc. Energetic modulation of nerves
US20160059044A1 (en) 2009-10-12 2016-03-03 Kona Medical, Inc. Energy delivery to intraparenchymal regions of the kidney to treat hypertension
US9119951B2 (en) 2009-10-12 2015-09-01 Kona Medical, Inc. Energetic modulation of nerves
US11998266B2 (en) 2009-10-12 2024-06-04 Otsuka Medical Devices Co., Ltd Intravascular energy delivery
US8295912B2 (en) 2009-10-12 2012-10-23 Kona Medical, Inc. Method and system to inhibit a function of a nerve traveling with an artery
US8986211B2 (en) 2009-10-12 2015-03-24 Kona Medical, Inc. Energetic modulation of nerves
CA2779842C (en) * 2009-11-04 2021-06-22 Arizona Board Of Regents For And On Behalf Of Arizona State University Devices and methods for modulating brain activity
US20110112394A1 (en) * 2009-11-11 2011-05-12 Mishelevich David J Neuromodulation of deep-brain targets using focused ultrasound
US20120053391A1 (en) * 2010-01-18 2012-03-01 Mishelevich David J Shaped and steered ultrasound for deep-brain neuromodulation
US20110190668A1 (en) * 2010-02-03 2011-08-04 Mishelevich David J Ultrasound neuromodulation of the sphenopalatine ganglion
US20130066350A1 (en) * 2010-01-18 2013-03-14 David J. Mishelevich Treatment planning for deep-brain neuromodulation
US20110130615A1 (en) * 2009-12-02 2011-06-02 Mishelevich David J Multi-modality neuromodulation of brain targets
US20110208094A1 (en) * 2010-02-21 2011-08-25 Mishelevich David J Ultrasound neuromodulation of the reticular activating system
US20160001096A1 (en) * 2009-11-11 2016-01-07 David J. Mishelevich Devices and methods for optimized neuromodulation and their application
US20110178442A1 (en) * 2010-01-18 2011-07-21 Mishelevich David J Patient feedback for control of ultrasound deep-brain neuromodulation
US20120197163A1 (en) * 2011-01-27 2012-08-02 Mishelevich David J Patterned control of ultrasound for neuromodulation
US20120283604A1 (en) * 2011-05-08 2012-11-08 Mishelevich David J Ultrasound neuromodulation treatment of movement disorders, including motor tremor, tourette's syndrome, and epilepsy
WO2011082408A2 (en) * 2009-12-31 2011-07-07 Zetroz Llc Low-profile ultrasound transducer
JP5866332B2 (en) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Molecules that allow photosensitive ions to pass through
US9492679B2 (en) 2010-07-16 2016-11-15 Rio Grande Neurosciences, Inc. Transcranial magnetic stimulation for altering susceptibility of tissue to pharmaceuticals and radiation
DE102010041654A1 (en) * 2010-09-29 2012-03-29 Zimmer Medizinsysteme Gmbh Radiation field applicator and method
US10568307B2 (en) 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CN106947741A (en) 2010-11-05 2017-07-14 斯坦福大学托管董事会 Photoactivation is fitted together to opsin and its application method
JP6355335B2 (en) 2010-11-05 2018-07-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Optogenetic control of reward-related behavior
AU2011323231B2 (en) 2010-11-05 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
JP6155192B2 (en) 2010-11-05 2017-06-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Central nervous system (CNS) dysfunction controlled by light
WO2012061681A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University. Control and characterization of memory function
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2012100290A1 (en) * 2011-01-24 2012-08-02 Newsouth Innovations Pty Limited Stimulation method for maintaining responsiveness of cells
US8891334B2 (en) * 2011-03-04 2014-11-18 Georgia Tech Research Corporation Compact, energy-efficient ultrasound imaging probes using CMUT arrays with integrated electronics
US9042201B2 (en) 2011-10-21 2015-05-26 Thync, Inc. Method and system for direct communication
JP6406581B2 (en) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Opsin polypeptides and uses thereof
EP2817068B1 (en) 2012-02-21 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
CN103479403B (en) * 2012-06-08 2016-06-22 长庚大学 System and method for guiding focused ultrasonic energy release by surgical navigation system
US11167154B2 (en) * 2012-08-22 2021-11-09 Medtronic, Inc. Ultrasound diagnostic and therapy management system and associated method
WO2014036170A1 (en) 2012-08-29 2014-03-06 Thync, Inc. Systems and devices for coupling ultrasound energy to a body
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014068577A2 (en) 2012-11-05 2014-05-08 Rainbow Medical Ltd. Controlled tissue ablation
CN204147427U (en) 2012-11-26 2015-02-11 塞恩克公司 Wearable electrocutaneous stimulation equipment
US9440070B2 (en) 2012-11-26 2016-09-13 Thyne Global, Inc. Wearable transdermal electrical stimulation devices and methods of using them
US9399126B2 (en) 2014-02-27 2016-07-26 Thync Global, Inc. Methods for user control of neurostimulation to modify a cognitive state
US10512794B2 (en) 2016-12-16 2019-12-24 Brainsonix Corporation Stereotactic frame
US9061133B2 (en) 2012-12-27 2015-06-23 Brainsonix Corporation Focused ultrasonic transducer navigation system
US10974078B2 (en) 2012-12-27 2021-04-13 Brainsonix Corporation Treating degenerative dementia with low intensity focused ultrasound pulsation (LIFUP) device
US12453853B2 (en) 2013-01-21 2025-10-28 Cala Health, Inc. Multi-modal stimulation for treating tremor
EP3912674A1 (en) 2013-01-21 2021-11-24 Cala Health, Inc. Devices for controlling tremor
WO2014127091A1 (en) * 2013-02-14 2014-08-21 Thync, Inc. Transcranial ultrasound systems
US9050053B2 (en) 2013-02-15 2015-06-09 Naimco, Inc. Ultrasound device with cavity for conductive medium
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
AU2014227600B2 (en) 2013-03-15 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
CA2908864A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
ES2696707T3 (en) 2013-06-29 2019-01-17 Cerevast Medical Inc Transcutaneous electrical stimulation devices and methods to modify or induce the cognitive state
CN105829538A (en) 2013-08-14 2016-08-03 小利兰·斯坦福大学托管委员会 Silicone-modified polyester coating
JP2017511129A (en) 2014-03-28 2017-04-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Genetically engineered photoactivated anion channel protein and methods of use thereof
EP3139853B1 (en) 2014-05-07 2018-12-19 Pythagoras Medical Ltd. Controlled tissue ablation apparatus
US9333334B2 (en) 2014-05-25 2016-05-10 Thync, Inc. Methods for attaching and wearing a neurostimulator
CN106413805A (en) 2014-06-02 2017-02-15 卡拉健康公司 Systems and methods for peripheral nerve stimulation to treat tremor
US10925579B2 (en) 2014-11-05 2021-02-23 Otsuka Medical Devices Co., Ltd. Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery
US10098539B2 (en) 2015-02-10 2018-10-16 The Trustees Of Columbia University In The City Of New York Systems and methods for non-invasive brain stimulation with ultrasound
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
CN112914514B (en) 2015-06-10 2024-12-13 卡拉健康公司 Systems and methods for peripheral nerve stimulation to treat tremor using a detachable treatment and monitoring unit
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
KR101750294B1 (en) * 2015-09-17 2017-06-26 한국과학기술연구원 brain to brain interface system applied to single brain
EP3352843B1 (en) 2015-09-23 2021-06-23 Cala Health, Inc. Device for peripheral nerve stimulation in the finger to treat hand tremors
WO2017132067A2 (en) 2016-01-21 2017-08-03 Cala Health, Inc. Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder
WO2017199240A2 (en) 2016-05-18 2017-11-23 Pythagoras Medical Ltd. Helical catheter
CN109689151B (en) 2016-07-08 2024-07-30 卡拉健康公司 System and method for stimulating N nerves with exactly N electrodes and improved dry electrodes
WO2018022902A1 (en) 2016-07-27 2018-02-01 The Trustees Of Columbia University In The City Of New York Methods and systems for peripheral nerve modulation using focused ultrasound
US11020617B2 (en) 2016-07-27 2021-06-01 The Trustees Of Columbia University In The City Of New York Methods and systems for peripheral nerve modulation using non ablative focused ultrasound with electromyography (EMG) monitoring
JP7133543B2 (en) 2016-08-25 2022-09-08 カラ ヘルス,インコーポレイテッド Systems and methods for treating cardiac dysfunction with peripheral nerve stimulation
WO2018067654A1 (en) * 2016-10-04 2018-04-12 Sanchez Hector Daniel Romo Devices and methods for selectively activating afferent nerve fibers
CN109906051A (en) 2016-10-31 2019-06-18 通用电气公司 neuromodulation technology
EP3606604A4 (en) 2017-04-03 2020-12-16 Cala Health, Inc. SYSTEMS, METHODS AND DEVICES FOR PERIPHERAL NEUROMODULATION FOR THE TREATMENT OF DISEASES RELATED TO OVERACTIVE BLADDER
KR101861963B1 (en) * 2017-06-30 2018-05-28 한국과학기술원 Method for stimulating, and apparatuses performing the same
WO2019143790A1 (en) 2018-01-17 2019-07-25 Cala Health, Inc. Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation
WO2020062050A1 (en) * 2018-09-28 2020-04-02 深圳迈瑞生物医疗电子股份有限公司 Ultrasound diagnostic instrument and method for switching ultrasound examination modes
US20230249006A1 (en) * 2019-06-07 2023-08-10 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel High Spatial Resolution Neuromodulation
US12186593B2 (en) * 2019-06-07 2025-01-07 The Board Of Trustees Of The Leland Stanford Junior University Pattern interference radiation force (PIRF) neural stimulators
US12251560B1 (en) 2019-08-13 2025-03-18 Cala Health, Inc. Connection quality determination for wearable neurostimulation systems
US11890468B1 (en) 2019-10-03 2024-02-06 Cala Health, Inc. Neurostimulation systems with event pattern detection and classification
US12453858B2 (en) 2019-12-02 2025-10-28 West Virginia University Board of Governors on behalf of West Virginia University Neuromodulatory methods for improving addiction using multi-dimensional feedback
US11850427B2 (en) 2019-12-02 2023-12-26 West Virginia University Board of Governors on behalf of West Virginia University Methods and systems of improving and monitoring addiction using cue reactivity
US11786760B2 (en) 2019-12-10 2023-10-17 GE Precision Healthcare LLC Multi-beam neuromodulation techniques
US11759661B2 (en) 2020-05-20 2023-09-19 Brainsonix Corporation Ultrasonic transducer treatment device
US11921271B2 (en) 2020-05-22 2024-03-05 The Board Of Trustees Of The Leland Stanford Junior Univeristy Multifocal macroscope for large field of view imaging of dynamic specimens
WO2022046764A1 (en) 2020-08-24 2022-03-03 Brainsonix Corporation Systems and methods for neuromodulation of neuronal circuits using transcranial focused microwave pulses
US20220168182A1 (en) * 2020-11-30 2022-06-02 Industrial Technology Research Institute Ultrasonic device and control method thereof
US12467932B2 (en) 2022-10-24 2025-11-11 West Virginia University Board of Governors on behalf of West Virginia University Methods of improving neurodegenerative disorders by targeted delivery of therapeutic agents
KR102626932B1 (en) * 2023-01-03 2024-01-23 주식회사 뉴머스 Patient customized helmet and manufacturing method thereof
US12458817B2 (en) 2023-11-21 2025-11-04 Sanmai Technologies, PBC Wearable closed loop TUS system

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2968302A (en) 1956-07-20 1961-01-17 Univ Illinois Multibeam focusing irradiator
US3131690A (en) 1962-10-22 1964-05-05 American Optical Corp Fiber optics devices
US3499437A (en) 1967-03-10 1970-03-10 Ultrasonic Systems Method and apparatus for treatment of organic structures and systems thereof with ultrasonic energy
US3567847A (en) 1969-01-06 1971-03-02 Edgar E Price Electro-optical display system
US4343301A (en) 1979-10-04 1982-08-10 Robert Indech Subcutaneous neural stimulation or local tissue destruction
US4559951A (en) 1982-11-29 1985-12-24 Cardiac Pacemakers, Inc. Catheter assembly
US4616231A (en) 1984-03-26 1986-10-07 Hughes Aircraft Company Narrow-band beam steering system
FR2580277B1 (en) 1985-04-15 1988-06-10 Oreal NOVEL NAPHTHALENIC DERIVATIVES WITH RETINOIC ACTION, THEIR PREPARATION METHOD AND MEDICINAL AND COSMETIC COMPOSITIONS CONTAINING THEM
US4865042A (en) 1985-08-16 1989-09-12 Hitachi, Ltd. Ultrasonic irradiation system
EP0335326B1 (en) 1988-03-28 1994-06-15 Canon Kabushiki Kaisha Ion permeable membrane and ion transport method by utilizing said membrane
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JP2882818B2 (en) 1989-09-08 1999-04-12 株式会社エス・エル・ティ・ジャパン Laser irradiation equipment
CA2028261C (en) 1989-10-28 1995-01-17 Won Suck Yang Non-invasive method and apparatus for measuring blood glucose concentration
US5032123A (en) 1989-12-28 1991-07-16 Cordis Corporation Laser catheter with radially divergent treatment beam
EP0574402B2 (en) 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
US5550316A (en) 1991-01-02 1996-08-27 Fox Chase Cancer Center Transgenic animal model system for human cutaneous melanoma
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5249575A (en) 1991-10-21 1993-10-05 Adm Tronics Unlimited, Inc. Corona discharge beam thermotherapy system
SE9103752D0 (en) 1991-12-18 1991-12-18 Astra Ab NEW COMPOUNDS
US5670113A (en) 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5739273A (en) 1992-02-12 1998-04-14 Yale University Transmembrane polypeptide and methods of use
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5330515A (en) 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5382516A (en) 1992-09-15 1995-01-17 Schleicher & Schuell, Inc. Method and devices for delivery of substrate for the detection of enzyme-linked, membrane-based binding assays
US6315772B1 (en) 1993-09-24 2001-11-13 Transmedica International, Inc. Laser assisted pharmaceutical delivery and fluid removal
US5527695A (en) 1993-01-29 1996-06-18 Purdue Research Foundation Controlled modification of eukaryotic genomes
EP0690913A1 (en) 1993-03-25 1996-01-10 The Regents Of The University Of California Expression of heterologous polypeptides in halobacteria
US5411540A (en) 1993-06-03 1995-05-02 Massachusetts Institute Of Technology Method and apparatus for preferential neuron stimulation
GB2278783A (en) * 1993-06-11 1994-12-14 Daniel Shellon Gluck Method of magnetically stimulating neural cells
US6346101B1 (en) 1993-07-19 2002-02-12 Research Foundation Of City College Of New York Photon-mediated introduction of biological materials into cells and/or cellular components
US5445608A (en) 1993-08-16 1995-08-29 James C. Chen Method and apparatus for providing light-activated therapy
JPH07171162A (en) 1993-09-07 1995-07-11 Olympus Optical Co Ltd Laser probe
US5470307A (en) 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
ATE386131T1 (en) 1994-04-13 2008-03-15 Univ Rockefeller AAV-MEDIATED DELIVERY OF DNA INTO CELLS OF THE NERVOUS SYSTEM
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US5495541A (en) 1994-04-19 1996-02-27 Murray; Steven C. Optical delivery device with high numerical aperture curved waveguide
US5503737A (en) 1994-07-25 1996-04-02 Ingersoll-Rand Company Air inflow restrictor for disc filters
US5807285A (en) 1994-08-18 1998-09-15 Ethicon-Endo Surgery, Inc. Medical applications of ultrasonic energy
US5520188A (en) 1994-11-02 1996-05-28 Focus Surgery Inc. Annular array transducer
US5795581A (en) 1995-03-31 1998-08-18 Sandia Corporation Controlled release of molecular components of dendrimer/bioactive complexes
US6334846B1 (en) 1995-03-31 2002-01-01 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
WO1996032076A1 (en) 1995-04-11 1996-10-17 Baxter Internatonal Inc. Tissue implant systems
US6342379B1 (en) 1995-06-07 2002-01-29 The Regents Of The University Of California Detection of transmembrane potentials by optical methods
US6480743B1 (en) 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US5755750A (en) 1995-11-13 1998-05-26 University Of Florida Method and apparatus for selectively inhibiting activity in nerve fibers
US5722426A (en) 1996-02-26 1998-03-03 Kolff; Jack Coronary light probe and method of use
US5703985A (en) 1996-04-29 1997-12-30 Eclipse Surgical Technologies, Inc. Optical fiber device and method for laser surgery procedures
US5939320A (en) 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5898058A (en) 1996-05-20 1999-04-27 Wellman, Inc. Method of post-polymerization stabilization of high activity catalysts in continuous polyethylene terephthalate production
US20040076613A1 (en) 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5741316A (en) 1996-12-02 1998-04-21 Light Sciences Limited Partnership Electromagnetic coil configurations for power transmission through tissue
US5756351A (en) 1997-01-13 1998-05-26 The Regents Of The University Of California Biomolecular optical sensors
US5782896A (en) 1997-01-29 1998-07-21 Light Sciences Limited Partnership Use of a shape memory alloy to modify the disposition of a device within an implantable medical probe
US5904659A (en) 1997-02-14 1999-05-18 Exogen, Inc. Ultrasonic treatment for wounds
US6436708B1 (en) 1997-04-17 2002-08-20 Paola Leone Delivery system for gene therapy to the brain
US5816256A (en) 1997-04-17 1998-10-06 Bioanalytical Systems, Inc. Movement--responsive system for conducting tests on freely-moving animals
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US5984861A (en) 1997-09-29 1999-11-16 Boston Scientific Corporation Endofluorescence imaging module for an endoscope
US6597954B1 (en) 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US6016449A (en) 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6647296B2 (en) 1997-10-27 2003-11-11 Neuropace, Inc. Implantable apparatus for treating neurological disorders
US6790652B1 (en) 1998-01-08 2004-09-14 Bioimage A/S Method and apparatus for high density format screening for bioactive molecules
AU3550099A (en) 1998-04-07 1999-10-25 Windy Hill Technology, Inc. Methods and devices for the localization of lesions in solid tissue
US6319241B1 (en) 1998-04-30 2001-11-20 Medtronic, Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US6108081A (en) 1998-07-20 2000-08-22 Battelle Memorial Institute Nonlinear vibrational microscopy
AU5898599A (en) 1998-08-19 2000-03-14 Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US6377842B1 (en) 1998-09-22 2002-04-23 Aurora Optics, Inc. Method for quantitative measurement of fluorescent and phosphorescent drugs within tissue utilizing a fiber optic probe
US6253109B1 (en) 1998-11-05 2001-06-26 Medtronic Inc. System for optimized brain stimulation
US7211054B1 (en) 1998-11-06 2007-05-01 University Of Rochester Method of treating a patient with a neurodegenerative disease using ultrasound
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US6224566B1 (en) 1999-05-04 2001-05-01 Cardiodyne, Inc. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
US6161045A (en) 1999-06-01 2000-12-12 Neuropace, Inc. Method for determining stimulation parameters for the treatment of epileptic seizures
US7655423B2 (en) 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6662039B2 (en) 1999-06-18 2003-12-09 The Trustees Of Columbia University In The City Of New York Optical probing of neuronal connections with fluorescent indicators
US20040034882A1 (en) 1999-07-15 2004-02-19 Vale Wylie W. Corticotropin releasing factor receptor 2 deficient mice and uses thereof
US7674463B1 (en) 1999-07-15 2010-03-09 Research Development Foundation Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
AU775394B2 (en) 1999-07-19 2004-07-29 St. Jude Medical, Atrial Fibrillation Division, Inc. Apparatus and method for ablating tissue
ES2152900B1 (en) 1999-07-23 2001-08-16 Palleja Xavier Estivill TRANSGENIC MOUSES AND OVEREXPRESSION MODEL OF GEN NTRK3 (TRKC) BASED ON THE SAME FOR THE STUDY AND MONITORING OF TREATMENTS OF ANXIETY, DEPRESSION AND RELATED PSYCHIATRIC DISEASES.
US6780490B1 (en) 1999-08-06 2004-08-24 Yukadenshi Co., Ltd. Tray for conveying magnetic head for magnetic disk
GB9923558D0 (en) 1999-10-05 1999-12-08 Oxford Biomedica Ltd Producer cell
GB9928248D0 (en) 1999-12-01 2000-01-26 Gill Steven S An implantable guide tube for neurosurgery
AU2001241420A1 (en) 2000-01-14 2001-07-24 Mitokor Screening assays using intramitochondrial calcium
US6595934B1 (en) * 2000-01-19 2003-07-22 Medtronic Xomed, Inc. Methods of skin rejuvenation using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US7706882B2 (en) * 2000-01-19 2010-04-27 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area
EP1255868B1 (en) 2000-02-18 2010-12-01 The Board Of Trustees Of The Leland Stanford Junior University Altered recombinases for genome modification
US6473639B1 (en) 2000-03-02 2002-10-29 Neuropace, Inc. Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures
AU2001295193A1 (en) 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
US6599281B1 (en) 2000-05-03 2003-07-29 Aspect Medical Systems, Inc. System and method for adaptive drug delivery
US6551346B2 (en) 2000-05-17 2003-04-22 Kent Crossley Method and apparatus to prevent infections
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
US7067626B2 (en) 2000-07-05 2006-06-27 Pharmacia & Upjohn Company Human ion channel proteins
US7399599B2 (en) 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
US6921413B2 (en) 2000-08-16 2005-07-26 Vanderbilt University Methods and devices for optical stimulation of neural tissues
US6567690B2 (en) 2000-10-16 2003-05-20 Cole Giller Method and apparatus for probe localization in brain matter
US7350522B2 (en) * 2000-10-17 2008-04-01 Sony Corporation Scanning method for applying ultrasonic acoustic data to the human neural cortex
US6536440B1 (en) 2000-10-17 2003-03-25 Sony Corporation Method and system for generating sensory data onto the human neural cortex
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6631283B2 (en) 2000-11-15 2003-10-07 Virginia Tech Intellectual Properties, Inc. B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
US6506154B1 (en) 2000-11-28 2003-01-14 Insightec-Txsonics, Ltd. Systems and methods for controlling a phased array focused ultrasound system
SE525540C2 (en) 2000-11-30 2005-03-08 Datainnovation I Lund Ab System and procedure for automatic sampling from a sample object
US20070196838A1 (en) 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6489115B2 (en) 2000-12-21 2002-12-03 The Board Of Regents Of The University Of Nebraska Genetic assays for trinucleotide repeat mutations in eukaryotic cells
US6615080B1 (en) 2001-03-29 2003-09-02 John Duncan Unsworth Neuromuscular electrical stimulation of the foot muscles for prevention of deep vein thrombosis and pulmonary embolism
US7047078B2 (en) 2001-03-30 2006-05-16 Case Western Reserve University Methods for stimulating components in, on, or near the pudendal nerve or its branches to achieve selective physiologic responses
AU2002303283A1 (en) 2001-04-04 2002-10-21 Irm Llc Methods for treating drug addiction
US7107996B2 (en) 2001-04-10 2006-09-19 Ganz Robert A Apparatus and method for treating atherosclerotic vascular disease through light sterilization
US6961045B2 (en) 2001-06-16 2005-11-01 Che-Chih Tsao Pattern projection techniques for volumetric 3D displays and 2D displays
US6810285B2 (en) 2001-06-28 2004-10-26 Neuropace, Inc. Seizure sensing and detection using an implantable device
US7144733B2 (en) 2001-08-16 2006-12-05 Sloan-Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
ATE360680T1 (en) 2001-08-23 2007-05-15 Univ California UNIVERSAL LIGHT-TURNED GENE PROMOTOR SYSTEM
US6974448B2 (en) 2001-08-30 2005-12-13 Medtronic, Inc. Method for convection enhanced delivery catheter to treat brain and other tumors
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
WO2003020103A2 (en) 2001-09-04 2003-03-13 Amit Technology Science & Medicine Ltd. Method of and device for therapeutic illumination of internal organs and tissues
US20040054952A1 (en) 2002-09-13 2004-03-18 Morrow James W. Device verification system and method
US20060057192A1 (en) 2001-09-28 2006-03-16 Kane Patrick D Localized non-invasive biological modulation system
US7175596B2 (en) 2001-10-29 2007-02-13 Insightec-Txsonics Ltd System and method for sensing and locating disturbances in an energy path of a focused ultrasound system
US8308784B2 (en) 2006-08-24 2012-11-13 Jackson Streeter Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease
US7303578B2 (en) 2001-11-01 2007-12-04 Photothera, Inc. Device and method for providing phototherapy to the brain
AU2002363478A1 (en) 2001-11-08 2003-05-19 Children's Medical Center Corporation Bacterial ion channel and a method for screening ion channel modulators
WO2003041496A1 (en) 2001-11-14 2003-05-22 Yamanouchi Pharmaceutical Co., Ltd. Transgenic animal
WO2003046141A2 (en) 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US20030104512A1 (en) 2001-11-30 2003-06-05 Freeman Alex R. Biosensors for single cell and multi cell analysis
US6873868B2 (en) 2001-12-31 2005-03-29 Infraredx, Inc. Multi-fiber catheter probe arrangement for tissue analysis or treatment
US7211055B2 (en) * 2002-01-15 2007-05-01 The Regents Of The University Of California System and method providing directional ultrasound therapy to skeletal joints
US6721603B2 (en) 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US6666857B2 (en) 2002-01-29 2003-12-23 Robert F. Smith Integrated wavefront-directed topography-controlled photoablation
EP1478348A4 (en) 2002-02-01 2008-06-18 Cleveland Clinic Foundation Microinfusion device
EP1476080A4 (en) * 2002-02-20 2010-06-02 Medicis Technologies Corp Ultrasonic treatment and imaging of adipose tissue
IL148299A (en) * 2002-02-21 2014-04-30 Technion Res & Dev Foundation Ultrasound cardiac stimulator
JP4363843B2 (en) 2002-03-08 2009-11-11 オリンパス株式会社 Capsule endoscope
US20030186249A1 (en) 2002-04-01 2003-10-02 Zairen Sun Human TARPP genes and polypeptides
US20070135875A1 (en) * 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
DE10216005A1 (en) 2002-04-11 2003-10-30 Max Planck Gesellschaft Use of biological photoreceptors as direct light-controlled ion channels
US7283861B2 (en) * 2002-04-30 2007-10-16 Alexander Bystritsky Methods for modifying electrical currents in neuronal circuits
US9592409B2 (en) 2002-04-30 2017-03-14 The Regents Of The University Of California Methods for modifying electrical currents in neuronal circuits
WO2003096045A1 (en) 2002-05-13 2003-11-20 Koninklijke Philips Electronics N.V. Reduction of susceptibility artifacts in subencoded single-shot magnetic resonance imaging
US7883846B2 (en) 2002-05-31 2011-02-08 Sloan-Kettering Institute For Cancer Research Heterologous stimulus-gated ion channels and methods of using same
EP1513584A2 (en) 2002-06-04 2005-03-16 Cyberkinetics, Inc. Optically-connected implants and related systems and methods of use
WO2003106486A1 (en) 2002-06-12 2003-12-24 Fraunhofer-Gelellschaft Zur Förderung Der Angewandten Forschung E.V. Vegetable protein preparations and use thereof
US7292890B2 (en) 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
US20050020945A1 (en) * 2002-07-02 2005-01-27 Tosaya Carol A. Acoustically-aided cerebrospinal-fluid manipulation for neurodegenerative disease therapy
WO2004021243A2 (en) 2002-08-09 2004-03-11 Siemens Aktiengesellschaft Method and computer program comprising program code means, and computer program product for analysing the activity of a pharmaceutical preparation
WO2004016315A1 (en) * 2002-08-19 2004-02-26 Arizona Board Regents Neurostimulator
ATE424448T1 (en) 2002-10-10 2009-03-15 Merck & Co Inc TEST METHODS FOR CONDITION-DEPENDENT CALCIUM CHANNEL AGONISTS/ANTAGONISTS
US7355033B2 (en) 2002-11-18 2008-04-08 Health Research, Inc. Screening for West Nile Virus antiviral therapy
AU2003297023A1 (en) 2002-12-16 2004-07-29 Genentech, Inc. Transgenic mice expressing human cd20
US20040122475A1 (en) 2002-12-18 2004-06-24 Myrick Andrew J. Electrochemical neuron systems
US20040216177A1 (en) 2003-04-25 2004-10-28 Otsuka Pharmaceutical Co., Ltd. Congenic rats containing a mutant GPR10 gene
US7377900B2 (en) * 2003-06-02 2008-05-27 Insightec - Image Guided Treatment Ltd. Endo-cavity focused ultrasound transducer
WO2005007233A2 (en) 2003-06-20 2005-01-27 Massachusetts Institute Of Technology Application of electrical stimulation for functional tissue engineering in vitro and in vivo
US7091500B2 (en) 2003-06-20 2006-08-15 Lucent Technologies Inc. Multi-photon endoscopic imaging system
JP2005034073A (en) 2003-07-16 2005-02-10 Masamitsu Iino Fluorescent probe for assaying myosin light chain phosphorylation
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005039696A1 (en) 2003-10-21 2005-05-06 The Regents Of The University Of Michigan Intracranial neural interface system
US6952097B2 (en) 2003-10-22 2005-10-04 Siemens Aktiengesellschaft Method for slice position planning of tomographic measurements, using statistical images
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
US20080119421A1 (en) * 2003-10-31 2008-05-22 Jack Tuszynski Process for treating a biological organism
WO2005053811A2 (en) 2003-11-21 2005-06-16 Johns Hopkins University Biomolecule partition motifs and uses thereof
US20050124897A1 (en) * 2003-12-03 2005-06-09 Scimed Life Systems, Inc. Apparatus and methods for delivering acoustic energy to body tissue
US7783349B2 (en) * 2006-04-10 2010-08-24 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
WO2005074932A1 (en) 2004-01-28 2005-08-18 Altana Pharma Ag The use of (s) - pantoprazole magnesium for the treatment of airway disorders
CN1236305C (en) 2004-02-03 2006-01-11 复旦大学 Preparation method for biologic photosensitive protein-nanometer semiconductor composite photoelectric electrode
US7662114B2 (en) * 2004-03-02 2010-02-16 Focus Surgery, Inc. Ultrasound phased arrays
US20050215764A1 (en) * 2004-03-24 2005-09-29 Tuszynski Jack A Biological polymer with differently charged portions
ITMI20040598A1 (en) 2004-03-26 2004-06-26 Carlotta Giorgi METHOD FOR DETECTION OF INTRACELLULAR PARAMETERS WITH LUMINESCENT PROTEIN PROBES FOR THE SCREENING OF MOLECULES ABLE TO ALTER THE SAID PARAMETERS
US8512219B2 (en) * 2004-04-19 2013-08-20 The Invention Science Fund I, Llc Bioelectromagnetic interface system
US7313442B2 (en) * 2004-04-30 2007-12-25 Advanced Neuromodulation Systems, Inc. Method of treating mood disorders and/or anxiety disorders by brain stimulation
US7670838B2 (en) 2004-05-24 2010-03-02 The Board Of Trustees Of The Leland Stanford Junior University Coupling of excitation and neurogenesis in neural stem/progenitor cells
US20050279354A1 (en) 2004-06-21 2005-12-22 Harvey Deutsch Structures and Methods for the Joint Delivery of Fluids and Light
US20060057614A1 (en) 2004-08-04 2006-03-16 Nathaniel Heintz Tethering neuropeptides and toxins for modulation of ion channels and receptors
US7699780B2 (en) * 2004-08-11 2010-04-20 Insightec—Image-Guided Treatment Ltd. Focused ultrasound system with adaptive anatomical aperture shaping
US8409099B2 (en) * 2004-08-26 2013-04-02 Insightec Ltd. Focused ultrasound system for surrounding a body tissue mass and treatment method
US8821559B2 (en) 2004-08-27 2014-09-02 Codman & Shurtleff, Inc. Light-based implants for treating Alzheimer's disease
US7603174B2 (en) * 2004-10-21 2009-10-13 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
US7544171B2 (en) * 2004-10-22 2009-06-09 General Patent Llc Methods for promoting nerve regeneration and neuronal growth and elongation
US7833257B2 (en) 2004-11-12 2010-11-16 Northwestern University Apparatus and methods for optical stimulation of the auditory nerve
EP1814630A4 (en) 2004-11-15 2008-05-07 Christopher Decharms Applications of the stimulation of neural tissue using light
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US7686839B2 (en) 2005-01-26 2010-03-30 Lumitex, Inc. Phototherapy treatment devices for applying area lighting to a wound
US7553284B2 (en) 2005-02-02 2009-06-30 Vaitekunas Jeffrey J Focused ultrasound for pain reduction
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US7548780B2 (en) 2005-02-22 2009-06-16 Cardiac Pacemakers, Inc. Cell therapy and neural stimulation for cardiac repair
US7288108B2 (en) 2005-03-14 2007-10-30 Codman & Shurtleff, Inc. Red light implant for treating Parkinson's disease
US20070059775A1 (en) 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
WO2006103678A2 (en) 2005-03-31 2006-10-05 Esther Mayer Probe device, system and method for photobiomodulation of tissue lining a body cavity
JP2006295350A (en) 2005-04-07 2006-10-26 Sony Corp Imaging apparatus and imaging result processing method
US9445211B2 (en) * 2005-04-11 2016-09-13 St. Jude Medical, Atrial Fibrillation Division, Inc. Methods for manufacturing high intensity ultrasound transducers
GB0508254D0 (en) 2005-04-23 2005-06-01 Smith & Nephew Ultrasound device
US7640057B2 (en) 2005-04-25 2009-12-29 Cardiac Pacemakers, Inc. Methods of providing neural markers for sensed autonomic nervous system activity
US8066908B2 (en) 2005-04-26 2011-11-29 Uvic Industry Partnerships Inc. Production of light from sol-gel derived thin films made with lanthanide doped nanoparticles, and preparation thereof
DK1879623T3 (en) 2005-05-02 2012-12-17 Genzyme Corp GENTERAPY FOR BACKGROUND DISEASES
CN1879906A (en) * 2005-06-15 2006-12-20 郑云峰 Magnetic stimulating device for nervous centralis system and its usage method
US20070027443A1 (en) 2005-06-29 2007-02-01 Ondine International, Ltd. Hand piece for the delivery of light and system employing the hand piece
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US7736382B2 (en) 2005-09-09 2010-06-15 Lockheed Martin Corporation Apparatus for optical stimulation of nerves and other animal tissue
US8852184B2 (en) 2005-09-15 2014-10-07 Cannuflow, Inc. Arthroscopic surgical temperature control system
US20080077200A1 (en) 2006-09-21 2008-03-27 Aculight Corporation Apparatus and method for stimulation of nerves and automated control of surgical instruments
US7610100B2 (en) 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US20070191906A1 (en) * 2006-02-13 2007-08-16 Anand Iyer Method and apparatus for selective nerve stimulation
US20070219600A1 (en) 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
US20070282404A1 (en) 2006-04-10 2007-12-06 University Of Rochester Side-firing linear optic array for interstitial optical therapy and monitoring using compact helical geometry
US20070253995A1 (en) 2006-04-28 2007-11-01 Medtronic, Inc. Drug Delivery Methods and Devices for Treating Stress Urinary Incontinence
US8057464B2 (en) 2006-05-03 2011-11-15 Light Sciences Oncology, Inc. Light transmission system for photoreactive therapy
WO2007131180A2 (en) 2006-05-04 2007-11-15 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US20080176076A1 (en) 2006-05-11 2008-07-24 University Of Victoria Innovation And Development Corporation Functionalized lanthanide rich nanoparticles and use thereof
US20080262411A1 (en) 2006-06-02 2008-10-23 Dobak John D Dynamic nerve stimulation in combination with other eating disorder treatment modalities
EP2550992B1 (en) * 2006-06-19 2015-08-19 Highland Instruments, Inc. Apparatus for stimulation of biological tissue
US7795632B2 (en) 2006-06-26 2010-09-14 Osram Sylvania Inc. Light emitting diode with direct view optic
US20080027505A1 (en) * 2006-07-26 2008-01-31 G&L Consulting, Llc System and method for treatment of headaches
WO2008014382A2 (en) 2006-07-26 2008-01-31 Case Western Reserve University System and method for controlling g-protein coupled receptor pathways
SG139588A1 (en) 2006-07-28 2008-02-29 St Microelectronics Asia Addressable led architecure
US20080033297A1 (en) * 2006-08-02 2008-02-07 Sliwa John W Neural tissue stimulation, assessment, mapping, and therapy utilizing targeted acoustic mechanisms
US7848797B2 (en) 2006-08-17 2010-12-07 Neurometrix, Inc. Motor unit number estimation (MUNE) for the assessment of neuromuscular function
US7521590B2 (en) 2006-09-01 2009-04-21 Korea Institute Of Science And Technology Phospholipase C β1 (PLCβ1) knockout mice as a model system for testing schizophrenia drugs
US10420948B2 (en) 2006-10-30 2019-09-24 Medtronic, Inc. Implantable medical device with variable data retransmission characteristics based upon data type
WO2008070765A2 (en) 2006-12-06 2008-06-12 Case Western Reserve University Light-sensitive constructs for inducing cell death and cell signaling
EE200600039A (en) 2006-12-12 2008-10-15 Tartu Ülikool Animal Transgenic Model for Modeling Pathological Anxiety, Method for Identifying Compounds Suitable for the Treatment of Pathological Anxiety Diseases or Conditions, and Method for Wfs1 Protein Targeting Against Pathological Anxiety
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US7883536B1 (en) 2007-01-19 2011-02-08 Lockheed Martin Corporation Hybrid optical-electrical probes
US8401609B2 (en) * 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US8282559B2 (en) 2007-03-09 2012-10-09 Philip Chidi Njemanze Method for inducing and monitoring long-term potentiation and long-term depression using transcranial doppler ultrasound device in head-down bed rest
US8139339B2 (en) 2007-03-16 2012-03-20 Old Dominion University Research Foundation Modulation of neuromuscular functions with ultrashort electrical pulses
US20080287821A1 (en) 2007-03-30 2008-11-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US8386312B2 (en) 2007-05-01 2013-02-26 The Nielsen Company (Us), Llc Neuro-informatics repository system
US20110165681A1 (en) 2009-02-26 2011-07-07 Massachusetts Institute Of Technology Light-Activated Proton Pumps and Applications Thereof
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
US9138596B2 (en) 2007-08-22 2015-09-22 Cardiac Pacemakers, Inc. Optical depolarization of cardiac tissue
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
DE112008003192T5 (en) 2007-11-26 2010-10-07 Micro-Transponder, Inc., Dallas Transmission coils Architecture
WO2009072123A2 (en) 2007-12-06 2009-06-11 Technion Research & Development Foundation Ltd. Method and system for optical stimulation of neurons
US8883719B2 (en) 2008-01-16 2014-11-11 University Of Connecticut Bacteriorhodopsin protein variants and methods of use for long term data storage
US20090254134A1 (en) * 2008-02-04 2009-10-08 Medtrode Inc. Hybrid ultrasound/electrode device for neural stimulation and recording
JP5544659B2 (en) 2008-03-24 2014-07-09 国立大学法人東北大学 Modified photoreceptor channel-type rhodopsin protein
CN102056625B (en) 2008-04-04 2015-11-25 免疫之光有限责任公司 Non-invasive systems and methods for in situ photobiomodulation
ES2608498T3 (en) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
CN102159713A (en) 2008-05-20 2011-08-17 Eos神经科学公司 Vectors for delivery of light-sensitive proteins and methods of use
EP2294208B1 (en) 2008-05-29 2013-05-08 The Board of Trustees of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
US8636653B2 (en) 2008-06-09 2014-01-28 Capso Vision, Inc. In vivo camera with multiple sources to illuminate tissue at different distances
CA2728238C (en) 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
CA2728402A1 (en) 2008-06-17 2009-12-23 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
EP2337489A4 (en) 2008-09-25 2014-11-19 Univ Columbia DEVICES, APPARATUS AND METHOD FOR OBTAINING PHOTOSTIMULATION AND IMAGING OF STRUCTURES
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
CA2758459A1 (en) 2009-03-24 2010-10-30 Spinal Modulation, Inc. Pain management with stimulation subthreshold to paresthesia
KR101081360B1 (en) 2009-03-25 2011-11-08 한국과학기술연구원 Photostimulation array apparatus
AR076361A1 (en) 2009-04-21 2011-06-08 Immunoligtht Llc PHARMACEUTICAL COMPOSITION KIT NON-INVASIVE ASCENDING ENERGY CONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION
WO2011005978A2 (en) 2009-07-08 2011-01-13 Duke University Methods of manipulating cell signaling
US20110112463A1 (en) 2009-11-12 2011-05-12 Jerry Silver Compositions and methods for treating a neuronal injury or neuronal disorders
US20110125078A1 (en) 2009-11-25 2011-05-26 Medtronic, Inc. Optical stimulation therapy
CN106137531B (en) 2010-02-26 2019-02-15 康奈尔大学 retinal prosthesis
JP5866332B2 (en) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Molecules that allow photosensitive ions to pass through
US20130225664A1 (en) 2010-04-05 2013-08-29 Alan Horsager Methods and compositions for decreasing chronic pain
US10051240B2 (en) 2010-06-14 2018-08-14 Howard Hughes Medical Institute Structured plane illumination microscopy
CN103168236B (en) 2010-08-23 2016-01-20 哈佛大学管理委员会 Optogenetic Probes for Membrane Potential Measurements
RU2595384C2 (en) 2010-09-08 2016-08-27 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Mutant channel rhodopsin-2
CN106267236A (en) 2010-11-05 2017-01-04 斯坦福大学托管董事会 The control of psychotic state and sign
WO2012061681A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University. Control and characterization of memory function
AU2011323231B2 (en) 2010-11-05 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Upconversion of light for use in optogenetic methods
US10568307B2 (en) 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
JP6155192B2 (en) 2010-11-05 2017-06-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Central nervous system (CNS) dysfunction controlled by light
JP6355335B2 (en) 2010-11-05 2018-07-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Optogenetic control of reward-related behavior
CN106947741A (en) 2010-11-05 2017-07-14 斯坦福大学托管董事会 Photoactivation is fitted together to opsin and its application method
US8957028B2 (en) 2010-11-13 2015-02-17 Massachusetts Institute Of Technology Red-shifted opsin molecules and uses thereof
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
US20120253261A1 (en) 2011-03-29 2012-10-04 Medtronic, Inc. Systems and methods for optogenetic modulation of cells within a patient
US20140128800A1 (en) 2011-06-28 2014-05-08 University Of Rochester Photoactivatable receptors and their uses
EP2736402B1 (en) 2011-07-25 2018-01-10 NeuroNexus Technologies, Inc. Opto-electrical device and method for artifact reduction
KR102023754B1 (en) 2011-07-27 2019-09-20 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Nanopore sensors for biomolecular characterization
JP6406581B2 (en) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Opsin polypeptides and uses thereof
EP2817068B1 (en) 2012-02-21 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
CN104471462B (en) 2012-02-23 2017-09-19 美国卫生与公共服务秘书部 Multifocal structured lighting microscopic system and method
AU2013235517B2 (en) 2012-03-20 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Non-human animal models of depression and methods of use thereof
EP3659518A1 (en) 2012-11-21 2020-06-03 Circuit Therapeutics, Inc. System and method for optogenetic therapy
US20150323787A1 (en) 2013-01-25 2015-11-12 The Trustees Of Columbia University In The City Of New York System, method and computer-accessible medium for depth of field imaging for three-dimensional sensing utilizing a spatial light modulator microscope arrangement
US20150112411A1 (en) 2013-10-18 2015-04-23 Varaya Photoceuticals, Llc High powered light emitting diode photobiology compositions, methods and systems
JP2017527419A (en) 2014-07-29 2017-09-21 サーキット セラピューティクス, インコーポレイテッド Systems and methods for optogenetic therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Also Published As

Publication number Publication date
US20090112133A1 (en) 2009-04-30
US10035027B2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
US10035027B2 (en) Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10143843B2 (en) Systems and methods for stimulating cellular function in tissue
US20210128915A1 (en) Apparatus and method for stimulation of biological tissue
JP2018064995A (en) Systems and methods for synchronizing stimulation of cellular function in tissue

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEISSEROTH, KARL;SCHNEIDER, M. BRET;REEL/FRAME:047176/0128

Effective date: 20081111

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION